Gene therapy for arrhythmic cardiomyopathy
The expression of desmophenin-2 in cardiac cells through AAV vectors has solved the problem of reduced inter-myocyte stability and sodium current in the center of arrhythmic cardiomyopathy, and achieved symptom relief and improved cardiac function.
Patent Information
- Application Number
- CN202380034073.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-14
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-22
AI Technical Summary
Arrhythmic cardiomyopathy is caused by mutation in desmosphenin-2 gene, which reduces mechanical stability between cardiomyocytes, damage to gap junctions and reduced sodium current, resulting in severe symptoms such as ventricular arrhythmia, syncope and sudden death. Limited treatment methods.
Desmospheric phenylain in heart cells using an adeno-associated virus (AAV) expression cassette containing 5'AAV reverse terminal repeat sequence, cardiac troponin T promoter and desmosphenylain-2 transgene. Visin-2, to improve mechanical stability and sodium current between cardiomyocytes and reduce right ventricular myocardial fibrosis.
Effectively reduce the severity of arrhythmic cardiomyopathy, delay its onset or eliminate symptoms, improve mechanical stability between cardiac myocardial cells, improve the gap junction function of heart tissue, increase sodium current in heart tissue, reduce fibrosis, and prolong survival and improve cardiac function.
Smart Images

Figure CN119013408A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 383,639 filed on November 14, 2022 and U.S. Provisional Application No. 63 / 311,840 filed on February 18, 2022, the contents of which are incorporated herein by reference in their entirety for all purposes.
[0003] Incorporation of Sequence Listing
[0004] The contents of the electronically submitted text file are incorporated herein by reference in their entirety: Computer readable format copy of the Sequence Listing (STRD_026_02WO_SeqList_ST26.xml, Record Date: February 6, 2023, File Size: approximately 44,684 bytes). Background Art
[0005] Arrhythmogenic cardiomyopathy is a rare familial disease that usually presents in adulthood and can cause ventricular tachycardia (fast heart rate) and sudden cardiac death in young, apparently healthy individuals. The clinical hallmarks of the disease are ventricular arrhythmias (abnormal heartbeats) that primarily originate in the right ventricle. The pathological hallmark of the disease is fibrofatty replacement of the right ventricular myocardium. Symptoms often include fluttering or pounding sensations in the chest (palpitations), dizziness, and fainting (syncope). Over time, patients may develop shortness of breath and abnormal swelling in the legs or abdomen. If the heart muscle is severely damaged in the late stages of the disease, it may lead to heart failure.
[0006] Arrhythmogenic cardiomyopathy is often caused by mutations in genes encoding proteins such as plakophilin-2 that are part of desmosomes. Desmosomes are specialized adhesion protein complexes located at intercellular junctions that facilitate attachment between cardiomyocytes, thereby maintaining the integrity of myocardial tissue. Mutations in genes encoding desmosomal proteins impair desmosome function, leading to myocardial damage and replacement of cardiac tissue with fatty or fibrotic tissue.
[0007] Standard care for ACM includes the use of medications (such as beta blockers and amiodarone), implantable cardioverter-defibrillators (ICDs), and catheter ablation to control symptoms.Therefore, there is a continuing need for disease-modifying therapeutic compositions and methods for treating ACM. Summary of the invention
[0008] The present disclosure provides a nucleic acid molecule comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises from 5' to 3': (i) 5' AAV inverted terminal repeat (ITR); (ii) a promoter; (iii) an arrhythmogenic cardiomyopathy-related transgene; and (iv) 3' AAV ITR. In some embodiments, the promoter is capable of expressing the transgene in cardiac cells. In some embodiments, the promoter includes a cardiac troponin T (TNNT2) promoter, such as a TNNT2 promoter comprising a nucleic acid sequence of SEQ ID NO: 4 or a sequence having at least 90% identity thereto. In some embodiments, the transgene encodes desmosome plaque protein-2, such as a transgene comprising a nucleic acid sequence of SEQ ID NO: 2 or a sequence having at least 90% identity thereto. In some embodiments, the AAV expression cassette comprises a nucleic acid sequence of SEQ ID NO: 12 or a sequence having at least 90% identity thereto.
[0009] The present disclosure also provides a plasmid comprising any of the nucleic acid molecules disclosed herein; and a cell comprising any of the nucleic acid molecules or plasmids disclosed herein. In addition, the present disclosure provides a method for producing a recombinant AAV vector, comprising contacting an AAV production cell with any of the nucleic acid molecules or plasmids disclosed herein. The present disclosure also provides a recombinant AAV vector, which is produced by any of the methods disclosed herein for producing a recombinant AAV vector. In some embodiments, the recombinant AAV vector is a single-stranded AAV (ssAAV). In some embodiments, the recombinant AAV vector is a self-complementary AAV (scAAV). In some embodiments, the AAV vector comprises the capsid protein of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV.
[0010] In some embodiments, the AAV vector comprises a capsid protein having one or more substitutions or mutations compared to the wild-type AAV capsid protein. For example, in some embodiments, the AAV vector comprises a capsid protein comprising: (i) an amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto, or (ii) an amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto, or (iii) an amino acid sequence of SEQ ID NO: 15 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising an amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising an amino acid sequence of SEQ ID NO: 13. In some embodiments, the AAV vector comprises a capsid protein comprising an amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising an amino acid sequence of SEQ ID NO: 14. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15. The present disclosure further provides a composition comprising any nucleic acid, any plasmid, any cell, or any recombinant AAV vector disclosed herein and a pharmaceutically acceptable carrier.
[0011] The present disclosure also provides a method for expressing an ACM-associated transgene in a cell, comprising: contacting the cell with any one of the nucleic acids, plasmids, cells, recombinant AAV vectors or compositions disclosed herein, thereby expressing the ACM-associated transgene in the cell.
[0012] The present disclosure also provides a method for expressing an ACM-associated transgene in a tissue, comprising: contacting the tissue with any of the nucleic acids, plasmids, cells, recombinant AAV vectors or compositions disclosed herein, thereby expressing the ACM-associated transgene in the tissue. In some embodiments, the tissue comprises at least one cell and at least one desmosomal junction.
[0013] In some embodiments, the cell is a cardiac cell, an endothelial cell, a skin cell, a bladder cell, or a gastrointestinal mucosal cell. In some embodiments, the cell is a cardiac cell. In some embodiments, the contacting step is performed in vitro, ex vivo, or in vivo. In some embodiments, the contacting step is performed in a subject in need. In some embodiments, the contacting step includes administering a therapeutically effective amount of a nucleic acid molecule, a plasmid, a recombinant AAV vector, or a composition to the subject. In some embodiments, the subject suffers from arrhythmogenic cardiomyopathy or is at risk of developing arrhythmogenic cardiomyopathy.
[0014] The present disclosure also provides a method for treating arrhythmogenic cardiomyopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the nucleic acids, plasmids, cells, recombinant AAV vectors, or compositions disclosed herein, thereby treating the subject's arrhythmogenic cardiomyopathy. In some embodiments, arrhythmogenic cardiomyopathy is arrhythmogenic right ventricular cardiomyopathy. In some embodiments, arrhythmogenic cardiomyopathy is associated with a gene mutation, promoted by a gene mutation, or caused by a gene mutation. In some embodiments, the gene mutation includes a mutation in a PKP2 gene. In some embodiments, a mutation in a PKP2 gene results in PKP2 haploinsufficiency.
[0015] In some embodiments, the method comprises reducing the severity of arrhythmogenic cardiomyopathy; delaying its onset or progression; and / or eliminating its symptoms. In some embodiments, symptoms of arrhythmogenic cardiomyopathy include: (a) reentrant ventricular tachycardia, (b) syncope, (c) sudden death, or (d) any combination thereof. In some embodiments, arrhythmogenic cardiomyopathy is associated with: (a) reduced mechanical stability between cardiomyocytes of the subject, (b) disrupted gap junctions in the subject's cardiac tissue, (c) reduced sodium currents in the subject's cardiac tissue, (d) fibrosis of the right ventricular myocardium, or (e) any combination thereof.
[0016] In some embodiments, the method comprises increasing mechanical stability between cardiomyocytes of the subject. In some embodiments, the method comprises improving the function of gap junctions in cardiac tissue of the subject. In some embodiments, the method comprises increasing sodium currents in cardiac tissue of the subject. In some embodiments, the method comprises reducing fibrosis of right ventricular myocardium of the subject.
[0017] In some embodiments, the subject is a human subject. In some embodiments, the nucleic acid molecule, plasmid, cell, recombinant AAV vector or composition is administered to the cardiac tissue of the subject. In some embodiments, the nucleic acid molecule, plasmid, cell, recombinant AAV vector or composition is administered to the left atrium, right atrium, left ventricle, right ventricle and / or septum. In some embodiments, the nucleic acid molecule, plasmid, cell, recombinant AAV vector or composition is administered to the subject by intravenous administration, intra-arterial administration, intra-aortic administration, direct cardiac injection, coronary artery perfusion, or any combination thereof.
[0018] These and other embodiments are described in greater detail in the detailed description set forth below. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication in color will be provided by the Office upon request and payment of the necessary fee.
[0020] Figure 1 A schematic diagram of the AAV expression cassette of SEQ ID NO:12 is shown, which contains the following elements: (i) 5'AAV ITR of SEQ ID NO:5, (ii) cardiac calcineurin T (TNNT2) promoter of SEQ ID NO:4; (iii) human β-globin (hBG) intron of SEQ ID NO:7; (iv) human PKP2a transgene sequence of SEQ ID NO:2; (v) bovine growth hormone (bGH) polyA signal of SEQ ID NO:8; and (vi) 3'AAV ITR of SEQ ID NO:6.
[0021] Figure 2 Shown is the inclusion Figure 1 Plasmid map of the AAV expression cassette shown in .
[0022] Figure 3A Shown are the fold changes in PKP2 mRNA expression compared to the housekeeping gene UBC in normal human iPSC-derived cardiomyocytes that were untreated (“wild type”), treated with antisense oligonucleotides (ASOs) against PKP2 to knock down expression (“PKP2 KD”), or knocked out and then treated with AAV.STRV47-hTNNT2.PKP2a at 50K MOI. Figure 3B Shown are the results of Western blot of PKP2 protein in wild-type cells, untreated PKP2 KD cells, and PKP2 KD cells treated with 50K MOI of AAV.STRV47-hTNNT2.PKP2a. Figure 3C Depicted Figure 3BQuantification of protein band intensity in .
[0023] Figure 4A Shown are the results of Western blot analysis of PKP2a protein expression in wild-type cardiomyocytes and CRISPR-induced PKP2 knockout ("PKP2-KO") iPSC cardiomyocytes that were untreated or transduced with rAAV encoding hTNNT2.PKP2a (AAV.STRV5-hTNNT2.PKP2a). Figure 4B is a graph showing quantification of PKP2a protein expression in wild-type cardiomyocytes and PKP2-KO iPSC cardiomyocytes that were untreated or transduced with rAAV encoding hTNNT2.PKP2a (AAV.STRV5-hTNNT2.PKP2a), normalized to GAPDH. Figure 4C Shown are immunofluorescence microscopy images of wild-type and PKP2-KO iPSC cardiomyocytes that were either untreated or transduced with rAAV encoding hTNNT2.PKP2a (AAV.STRV5-hTNNT2.PKP2a).
[0024] Figure 5A Figure 2 shows the use of FLIPR calcium 6 ( i3x) Graph of spontaneous calcium transients measured. Figure 5B and 5C It is shown that in PKP2-KO iPSC cardiomyocytes ( Figure 5C ) and PKP2-KO iPSC cardiomyocytes transduced with control AAV.STRV5-Cbh.GFP ( Figure 5B ) using FLIPR Calcium 6 ( i3x) Graph of spontaneous calcium transients measured by PKP2, demonstrating that loss of PKP2 function results in early post-transients. Figure 5D Figure 2 shows the use of FLIPR calcium 6 ( Figure 3x) shows the disappearance of the early post-transient after transduction with AAV.STRV5-hTNNT2.PKP2a.
[0025] Fig. 6A is a graph showing vector copy number (VCN) in heart tissue of WT mice 21 days after IV injection of AAV.STRV47-hTNNT2.PKP2a via the tail vein (5e13 vg / kg). Figure 6Bis a graph showing PKP2 mRNA levels in heart tissue of WT mice 21 days after IV injection of AAV.STRV47-hTNNT2.PKP2a via the tail vein (5e13 vg / kg). Figure 6C is a Western blot showing human PKP2 protein in cardiac tissue extracts of WT mice 21 days after IV injection of AAV.STRV47-hTNNT2.PKP2a via the tail vein (5e13 vg / kg). Fig.6D Depicted Figure 6C Quantification of protein band intensity in .
[0026] Figure 7 Shown is the design of the tamoxifen-induced cardiac-specific PKP2 knockout mouse model used to study treatment with AAV.STRV5-hTNNT2.PKP2a or AAV.STR V84-hTNNT2.PKP2a.
[0027] Fig. 8A The combined overall survival of Cohort 1 and Cohort 2 over time for the indicated groups of mice is shown. See also Table B. Figure 8B Is a graph showing the survival probability of the following mice calculated using Kaplan-Meier curves using GraphPad Prism: untreated PKP2-cKO mice (n=5); mice with normal PKP2 function, i.e., Pkp2 wt / wt; Cre+ ("WT, Cre+"; n=5) and Pkp2 fl / fl; Cre- (FL, Cre-; n=4) controls; and PKP2-cKO mice treated with AAV.STRV5-hTTNT2.PKP2a (n=7). The study was terminated 54 days after injection of tamoxifen (dpi).
[0028] Fig. 9A is a graph showing vector copy number (VCN) in liver and heart tissue of PKP2 cardiac knockout mice 70 days after IV injection of AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a via the tail vein (5e13 vg / kg). Fig. 9B is a graph showing PKP2 mRNA levels in liver and heart tissues of PKP2 cardiac knockout mice 70 days after IV injection of AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a via the tail vein (5e13 vg / kg).
[0029] Fig. 10AWestern blot showing human PKP2 protein bands in heart tissue extracts of individual Group 2 mice (PKP2 wt / wt; Cre+), Group 3 mice (PKP2 fl / fl; Cre-), Group 1 mice (PKP2 fl / fl; Cre+), and treated PKP2 fl / fl; Cre+ mice 70 days after IV injection of AAV.STRV5-hTNNT2.PKP2a (Group 4) or AAV.STRV84-hTNNT2.PKP2a (Group 5) via the tail vein (5e13 vg / kg). Fig. 10B Total protein loading controls are shown. See also Table E in Example 6.
[0030] Figures 11A-11E are images showing PKP2 localization by immunohistochemistry in the following mice; PKP2wt / wt; Cre+ mice ( Fig.11A );PKP2 fl / fl;Cre-, tamoxifen-treated mice ( Fig. 11B ); PKP2 fl / fl, Cre+ and tamoxifen-treated mice ( Fig. 11C ); PKP2 fl / fl, Cre+ and tamoxifen-treated mice, which were also treated with 5e13vg / kg AAV.STRV5-hTNNT2.PKP2a vector ( Fig.11D ) or 5e13vg / kg AAV.STR V84-hTNNT2.PKP2a vector ( Fig.11E )treat.
[0031] Figures 12A-12B Figure 2 shows the quantitative left ventricular ejection fraction (LVEF) of control mice with wild-type PKP2 function (WT; Cre+ mice and floxed; Cre- mice), PKP2-cKO mice, and PKP2-cKO mice treated with AAV.STRV5-hTNN T2.PKP2a ( Fig. 12A ) and systolic right ventricular area (RV area-S) ( Fig. 12B ) of biweekly echocardiograms. Figures 12C-12D Figure 2 shows LVEF in control mice with wild-type PKP2 function (WT; Cre+ mice and floxed; Cre- mice), PKP2-cKO mice, and PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a at 42 dpi ( Fig. 12C ) and RV area-S( Fig.12D ). *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001.
[0032] Fig.13A Western blots are shown showing PKP2 protein bands in WT cardiac tissue extracts (lane 2); antisense oligonucleotide knockout in iPSC-derived cardiomyocytes ("-control KD") (lane 3); PKP2-cKO mice ("-control cKO") (lane 4); cardiomyocyte lysates transfected with AAV.STRV84-hTNNT2.PKP2a ("+control") (lanes 5-13); and PKP2-cardiac knockout mice treated with AAV.STRV5-hTNNT2.PKP2a ("treated") (lanes 14-20), where the PKP2a protein band is highlighted with an arrow (expected human size 92-97 kDa, expected mouse PKP2 size 88 kDa). The blue Coomassie highlights indicate the total protein loaded in each lane. Fig. 13B is a graph showing quantification of PKP2 protein bands observed in western blots generated from mouse heart tissue of the following mice: PKP2-cardiac knockout mice ("-control"); WT, Cre+ mice ("+control"); FL, Cre- mice ("+control"), and PKP2-cardiac knockout mice treated with AAV.STRV5-hTNNT2.PKP2a ("hTNNT2.PKP2a-treated"), indicating that treatment of PKP2-cardiac gene knockout mice with AAV.STRV5-hTNNT2.PKP2a restored PKP2 levels in the heart. Fig. 13C is a graph showing vector copy number / μg DNA in heart and liver tissues of PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a, as measured by qPCR. Fig.13D is a graph showing PKP2a mRNA transcript levels in heart and liver tissues of PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a, as measured by RT-qPCR, demonstrating tissue-specific expression in the heart. ****p<0.0001.
[0033] Figures 14A-14D are compared with -control (PKP2-cardiac knockout mice; Fig.14A ) and + controls (FL, Cre- mice; Fig. 14B ) animals treated with AAV.STRV84-hTNNT2.PKP2a ( Fig.14D ) or treated with AAV.STRV5-hTTNT2.PKP2a ( Fig. 14C) of the right ventricle of PKP2-cKO mice. Masson trichrome images (top row) show collagen in blue. Corresponding H&E images (bottom row) are shown. Images show that hTNNT2.PKP2a treatment reduces RV fibrosis.
[0034] Fig.15 Shows Figures 14A-14D Quantification of fibrosis is shown in the -Control (PKP2-cKO) column. Fig.14A Quantitative. Fig. 14B Quantification of can be seen in the + control (FL, Cre-) column. In the AAV.STRV5-hTNNT2.PKP2a column, Fig. 14C Quantification of. In AAV.STRV84-hTNNT2.PKP2a, it can be seen Fig.14D +control (wt, Cre+) is an additional positive control showing the quantification of fibrosis staining in wild-type animals.
[0035] Figures 16A-16B Mouse PKP2 (mPKP2 (SEQ ID NO: 20)) is shown in AAV particles containing a capsid protein having the amino acid sequence of SEQ ID NO: 15 ( Fig.16A ) and human PKP2 (hPKP2 (SEQ ID NO: 2)) ( Fig. 16B ) Correlation between transgene dose and vector copy number in the heart or liver. For both transgenes, vector copy number in the liver was approximately 1-2 logs higher than that in the heart.
[0036] Figures 17A-17B Mouse PKP2 expressed in heart and liver ( Fig.17A ) and human PKP2 ( Fig. 17B ) Correlation between transgene dosage and mRNA.
[0037] Fig.18 Western blots are shown showing mouse PKP2 protein bands in cardiac tissue extracts of mice treated with mPKP2. WT (Group 1); fl / fl Cre- (Group 2); fl / fl Cre+ (Group 3); ultra-low dose (Group 4); low dose group (Group 5); medium dose (Group 6); and high dose (Group 7), where the PKP2a protein band is highlighted with an arrow (expected human size is 92-97 kDa, expected mouse PKP2 size is 88 kDa). The blue Coomassie bright color indicates the total protein loaded in each lane.
[0038] Fig.19Western blots are shown showing human PKP2 protein bands in heart tissue extracts of hPKP2 treated mice. WT (Group 1); fl / fl Cre- (Group 2); fl / fl Cre+ (Group 3); low dose (Group 8); and high dose group (Group 9), where the PKP2a protein band is highlighted with an arrow (expected human size is 92-97 kDa, expected mouse PKP2 size is 88 kDa). The blue Coomassie color indicates the total protein loaded in each lane.
[0039] Fig. 20 Western blots are shown showing mouse PKP2 protein bands in left liver tissue extracts of mPKP2 treated mice. WT (Group 1); fl / fl Cre- (Group 2); fl / fl Cre+ (Group 3); ultra-low dose (Group 4); low dose group (Group 5); medium dose (Group 6); and high dose (Group 7), where the PKP2a protein band is highlighted with an arrow (expected human size is 92-97 kDa, expected mouse PKP2 size is 88 kDa). The blue Coomassie bright color indicates the total protein loaded in each lane.
[0040] Fig.21 Western blots are shown showing human PKP2 protein bands in left liver tissue extracts of hPKP2 treated mice. WT (Group 1); fl / fl Cre- (Group 2); fl / fl Cre+ (Group 3); low dose (Group 8); and high dose group (Group 9), where the PKP2a protein band is highlighted with an arrow (expected human size is 92-97 kDa, expected mouse PKP2 size is 88 kDa). The blue Coomassie color indicates the total protein loaded in each lane.
[0041] Figures 22A-22B Shown are mice injected with increasing doses of STRV84-PKP2 ( Fig.22A ) or STRV84-human PKP2 ( Fig. 22B ) increased the survival probability of ARVC mice (PKP2 fl / fl; Cre+).
[0042] Figures 23A-23F Shown is the increase in rescue of ARVC mice relative to doses of mPKP2 (ultra-low, low, medium and high) in terms of: ( Fig.23A ) ejection fraction; Fig. 23B )LV volume; Fig.23C ) stroke volume; Fig.23D ) shorten the fraction by a percentage; Fig.23E ) cardiac output; and ( Fig.23F) Left ventricular outflow tract velocity time integral (LVOT·VTI).
[0043] Figures 24A-24F Shown is an increase in rescue of ARVC mice relative to doses of mPKP2 (low and high): ( Fig.24A ) ejection fraction; Fig. 24B )LV volume; Fig.24C ) stroke volume; Fig.24D ) shorten the fraction by a percentage; Fig.24E ) cardiac output; and ( Fig.24F )LVOT·VTI. DETAILED DESCRIPTION
[0044] Approximately 40-60% of patients with ACM have mutations in genes encoding desmosomal proteins, with autosomal dominant mutations in PKP2 (encoding desmosomal plaque phycin-2) being the most prominent (approximately 50-70%). The estimated prevalence of ACM with PKP2 haploinsufficiency is approximately 1:6,000 to 1:25,000. At the cellular level, reduction or elimination of PKP2 function leads to reduced mechanical stability between cardiomyocytes, disruption of gap junctions (such as those containing connexin 43), and reduced sodium currents. These cellular effects lead to right ventricular myocardial fibrosis, which can lead to reentrant ventricular tachycardia, syncope, and sudden death.
[0045] PKP2 encodes desmosome plaque protein-2, which is one of the three desmosome plaque proteins expressed in cardiac progenitor cells and differentiated cardiomyocytes. Desmosome plaque protein-2 is also expressed in other cell types with desmosome connections, such as endothelial cells. Desmosome plaque protein-2 is a desmosomal structural protein, which connects the intermediate filament network in cardiac cells to intercellular cadherin, desmoplaque protein and desmoglein. Desmosome plaque protein-2 also plays a role in the recruitment and stabilization of other desmosomal proteins, and this contributes to the integrity and function of cardiac cell desmosomes, and therefore contributes to the integrity and function of the myocardium.
[0046] The present disclosure provides nucleic acids (comprising AAV expression cassettes), AAV vectors and compositions used in methods for treating diseases associated with arrhythmogenic cardiomyopathy-related genes such as PKP2 mutations and / or delaying their onset. In addition, methods for treating arrhythmogenic cardiomyopathy and / or delaying its onset are provided herein.
[0047] definition
[0048] The following terms are used in the description and appended claims herein:
[0049] The singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0050] In addition, the term "about" as used herein when referring to a measurable value, such as the length of a polynucleotide or polypeptide sequence, dosage, time, temperature, etc., is intended to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5% or even ±0.1% of the particular amount.
[0051] Furthermore, as used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as no combinations when interpreted in the alternative form ("or").
[0052] The term "wild-type" is a term understood by those skilled in the art and means the typical form of an organism, virus strain, gene, protein or feature that occurs in nature, as distinguished from mutant or variant forms. For example, a wild-type protein is the typical form of the protein as it occurs in nature.
[0053] The term "mutantin" is a term understood by those skilled in the art, and refers to a protein that is distinguished from a wild-type protein based on the presence of an amino acid modification (e.g., amino acid substitution, insertion, and / or deletion). The term "mutant gene" is a term understood by those skilled in the art, and refers to a gene that is distinguished from a wild-type gene based on the presence of a nucleic acid modification (e.g., nucleic acid substitution, insertion, and / or deletion). In some embodiments, a mutant gene encodes a mutant protein.
[0054] "Nucleic acid" or "polynucleotide" is a sequence of nucleotide bases, such as RNA, DNA or DNA-RNA hybrid sequences (including naturally occurring and non-naturally occurring nucleotides). In some embodiments, the nucleic acid of the present disclosure is a single-stranded or double-stranded DNA sequence. The length of the nucleic acid can be 1-1,000, 1,000-10,000, 10,000-100,000, 100,000-1 million or more than 1 million nucleotides. Nucleic acids will generally contain phosphodiester bonds, although in some cases, the included nucleic acid analogs may have alternating main chains, including, for example, phosphoramide, thiophosphate, dithiophosphate, O-methylphosphoramidite bonds and peptide nucleic acid main chains and bonds. Other similar nucleic acids include nucleic acids with positive main chains, nonionic main chains and non-ribose main chains. Nucleic acids containing one or more carbocyclic sugars are also included in the definition of nucleic acids. These modifications of the ribose phosphate main chain can promote the addition of labels, or increase the stability and half-life of such molecules in physiological environments. The nucleic acids of the present disclosure can be linear, or can be circular (eg, a plasmid).
[0055] As used herein, the term "promoter" refers to one or more nucleic acid control sequences that direct transcription of an operably linked nucleic acid. A promoter may include a nucleic acid sequence near a transcription start site, such as a TATA element. A promoter may also include a cis-acting polynucleotide sequence that can be bound by a transcription factor.
[0056] A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional connection between a nucleic acid expression control sequence (such as a promoter or transcription factor binding site array) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
[0057] An "AAV expression cassette" is a nucleic acid that is packaged into a recombinant AAV vector and contains sequences encoding one or more transgenes. When the AAV vector is contacted with a target cell, the transgene is expressed by the target cell.
[0058] As used herein, the term "virus vector," "viral vector," or "gene delivery vector" refers to a viral particle that acts as a nucleic acid delivery vector and comprises a nucleic acid (e.g., an AAV expression cassette) packaged within the viral particle. Exemplary viral vectors of the present disclosure include adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, and retroviral vectors.
[0059] As used herein, the term "adeno-associated virus" (AAV) includes, but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including type 3A and type 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, AAV rh32.33, AAV rh8, AAV rh10, AAV rh74, AAVhu.68, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, snake AAV, bearded dragon AAV, AAV2i8, AAV2g9, AAV-LK03, AAV7m8, AAV Anc80, AAV PHP.B, and any other AAV now known or later discovered. See, e.g., Table 1.
[0060] Table 1: Adeno-associated virus serotypes
[0061]
[0062]
[0063]
[0064] The term "virus-producing cell", "virus-producing cell line" or "virus-producing cell" refers to a cell used to produce a viral vector. HEK293 and 239T cells are common virus-producing cell lines. Table 2 below lists exemplary virus-producing cell lines for various viral vectors.
[0065] Table 2: Exemplary virus producing cell lines
[0066]
[0067] "HEK293" refers to a cell line originally derived from human embryonic kidney cells grown in tissue culture. The HEK293 cell line is easy to grow in culture and is commonly used for virus production. As used herein, "HEK293" may also refer to one or more variant HEK293 cell lines, i.e., cell lines derived from the original HEK293 cell line, which additionally comprise one or more genetic changes. Many variant HEK293 lines have been developed and optimized for one or more specific applications. For example, the 293T cell line contains the SV40 large T antigen, which allows episomal replication of a transfection plasmid containing the SV40 origin of replication, thereby resulting in increased expression of the desired gene product.
[0068] "Sf9" refers to an insect cell line that is a clonal isolate derived from the parental Spodoptera frugiperda cell line IPLB-Sf-21-AE. Sf9 cells can be grown in the absence of serum and can be cultured either attached or in suspension.
[0069] "Transfection reagent" means a composition that enhances the transfer of nucleic acids into cells. Some transfection reagents commonly used in the art include one or more lipids (e.g., lipofectamine ) that bind to nucleic acids and cell surfaces. TM ).
[0070] As used herein, "sequence identity" refers to the degree that two optimally aligned polynucleotides or polypeptide sequences are constant in the entire component (e.g., nucleotide or amino acid) alignment window. The "identity score" of the alignment fragment of a test sequence and a reference sequence is the number of identical components common to two alignment sequences divided by the total number of components in the reference sequence fragment, i.e., the entire reference sequence or the smaller determined portion of the reference sequence. "Identity percentage" is the identity score multiplied by 100. Computer programs and mathematical algorithms can be used to determine the degree of identity (homology) between two sequences. The alignment program Clustal Omega available at www.ebi.ac.uk / Tools / msa / clustalo can be used to calculate the identity percentage using default parameters. See Sievers et al., "Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega." (October 11, 2011) Molecular systems biology 7:539.
[0071] As used herein, "treatment" or "treating" or "alleviate" or "ameliorate" are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results, including but not limited to therapeutic benefit and / or prophylactic benefit. Therapeutic benefit refers to any treatment-related improvement or effect on one or more diseases, disorders, or symptoms under treatment. For prophylactic benefit, the composition can be administered to a subject at risk for developing a particular disease, disorder, or symptom, or to a subject reporting one or more physiological symptoms of a disease, even though the disease, disorder, or symptom may not yet be manifested.
[0072] The terms "subject", "individual" and "patient" are used interchangeably herein and refer to vertebrates, such as mammals. The mammal can be, for example, a mouse, rat, rabbit, cat, dog, pig, sheep, horse, non-human primate (e.g., cynomolgus monkey, chimpanzee) or human. Tissues, cells or derivatives thereof of subjects obtained in vivo or cultured in vitro are also contemplated. Human subjects can be adults, adolescents, children (2 to 14 years old), infants (1 to 24 months) or newborns (up to 1 month). In some embodiments, an adult is about 65 years old or older, or about 60 years old or older. In some embodiments, the subject is a pregnant woman or a woman intending to become pregnant.
[0073] The term "effective amount" or "therapeutically effective amount" refers to the amount of an agent sufficient to achieve a result, e.g., to achieve a beneficial or desired result. The therapeutically effective amount may vary depending on one or more of the subject and disease condition being treated, the subject's weight and age, the severity of the disease condition, the mode of administration, etc., which can be readily determined by one of ordinary skill in the art. The specific dosage may vary depending on one or more of the specific agent selected, the dosing regimen followed, whether it is administered in combination with other compounds, the timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
[0074] As used herein, the term "gene therapy" refers to the process of introducing genetic material into cells to compensate for an abnormal gene or to produce a therapeutic protein.
[0075] As used herein, "left ventricular ejection fraction" refers to a measurement of how much blood the left ventricle pumps out each time it contracts, expressed as a percentage. For example, an ejection fraction of 60% means that 60% of the total amount of blood in the left ventricle is pushed out with each heartbeat. The left ventricular ejection fraction can be calculated based on the results of tests such as echocardiograms, MUGA scans, CAT scans, cardiac catheterizations, and nuclear stress tests.
[0076] As used herein, the term "right ventricular area" refers to the measurement of right ventricular area by using long-axis B-mode echocardiography. This measures a two-dimensional plane of the heart oriented along the long axis.
[0077] AAV expression cassette
[0078] The present disclosure provides one or more adeno-associated virus (AAV) expression cassettes comprising nucleic acid sequences. In some embodiments, the AAV expression cassette comprises a 5' inverted terminal repeat (ITR), a promoter, a transgene, and a 3' ITR. In some embodiments, the transgene is an arrhythmogenic cardiomyopathy-related gene. In some embodiments, the AAV expression cassette comprises a Kozak sequence, a polyadenylation sequence, and / or a stuffer sequence.
[0079] In some embodiments, the AAV expression cassette comprises the nucleic acid sequence of SEQ ID NO: 12, or a sequence having at least 70% identity thereto (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity thereto, including all values and subranges therebetween). In some embodiments, the AAV expression cassette comprises the nucleic acid sequence of SEQ ID NO: 12.
[0080] (i) Inverted terminal repeats
[0081] Inverted terminal repeats or ITR sequences are sequences that mediate AAV proviral integration and AAV DNA packaging into virions. ITRs are involved in various activities in the AAV life cycle. For example, ITR sequences that can form hairpin structures play a role in excision from plasmids, replication of the vector genome, and integration and rescue from the host cell genome.
[0082] The AAV expression cassette of the present disclosure may comprise a 5' ITR and a 3' ITR. The ITR sequence may be about 110 to about 160 nucleotides in length, for example, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, or 160 nucleotides in length. In some embodiments, the length of the ITR sequence can be about 141 nucleotides. In some embodiments, the 5'ITR is the same length as the 3'ITR. In some embodiments, the 5'ITR and the 3'ITR have different lengths. In some embodiments, the 5'ITR is longer than the 3'ITR, and in other embodiments, the 3'ITR is longer than the 5'ITR.
[0083] The ITR can be isolated or derived from the genome of any AAV, such as the AAVs listed in Table 1. In some embodiments, at least one of the 5'ITR and the 3'ITR is isolated or derived from the genome of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV, or bovine AAV. In some embodiments, at least one of the 5'ITR and the 3'ITR can be a wild-type or mutant ITR isolated or derived from a member of another parvovirus species other than AAV. For example, in some embodiments, the ITR can be a wild-type or mutant ITR isolated or derived from bocavirus or parvovirus B19.
[0084] In some embodiments, the ITR comprises a modification that promotes the production of scAAV. In some embodiments, the modification that promotes the production of scAAV is to delete the terminal resolution sequence (TRS) from the ITR. In some embodiments, the 5'ITR is a wild-type ITR, and the 3'ITR is a mutant ITR lacking a terminal resolution sequence. In some embodiments, the 3'ITR is a wild-type ITR, and the 5'ITR is a mutant ITR lacking a terminal resolution sequence. In some embodiments, the terminal resolution sequence is not present in both the 5'ITR and the 3'ITR. In other embodiments, the modification that promotes the production of scAAV is to replace the ITR with a different hairpin-forming sequence, such as a short hairpin (sh) RNA-forming sequence.
[0085] In some embodiments, the 5'ITR may comprise a sequence of SEQ ID NO: 5, or a sequence having at least 70% identity thereto (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity thereto, including all values and subranges therebetween). In some embodiments, the 3'ITR may comprise a sequence of SEQ ID NO: 6, or a sequence having at least 70% identity thereto (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity thereto, including all values and subranges therebetween). In some embodiments, the 5'ITR comprises the sequence of SEQ ID NO: 5, and the 3'ITR comprises the sequence of SEQ ID NO: 6.
[0086] In some embodiments, the AAV expression cassette comprises one or more "alternative" ITRs, i.e., non-ITR sequences that have the same function as the ITRs. See, e.g., Xie, J. et al., Mol. Ther., 25(6): 1363-1374 (2017). In some embodiments, the ITRs in the AAV expression cassette are replaced by alternative ITRs. In some embodiments, the alternative ITRs comprise hairpin-forming sequences. In some embodiments, the alternative ITRs are shRNA-forming sequences.
[0087] (ii) Promoter
[0088] In some embodiments, the AAV expression cassette described herein comprises a promoter. In some embodiments, the promoter is a synthetic promoter. In some embodiments, the promoter may comprise a nucleic acid sequence derived from an endogenous promoter and / or an endogenous enhancer.
[0089] In some embodiments, the promoter comprises a nucleic acid sequence derived from one or more promoters commonly used in the field of gene expression. For example, in some embodiments, the promoter further comprises a nucleic acid sequence derived from a CMV promoter, an SV40 early promoter, an SV40 late promoter, a metallothionein promoter, a mouse mammary tumor virus (MMTV) promoter, a Rous sarcoma virus (RSV) promoter, a polyhedrin promoter, a chicken β-actin (CBA) promoter, a dihydrofolate reductase (DHFR) promoter, and a phosphoglycerol kinase (PGK) promoter. In some embodiments, the promoter comprises a nucleic acid sequence derived from a chicken β-actin (CBA) promoter, an EF-1α promoter, or an EF-1α short promoter.
[0090] In some embodiments, the promoter is capable of expressing a transgene in cardiac cells. In some embodiments, the promoter is a cell-specific promoter, such as a cardiac cell-specific promoter. As used herein, a "cell-specific promoter" refers to a promoter that is capable of expressing a transgene at a higher level in a specific cell (e.g., a cardiac cell) compared to a control cell (e.g., a non-cardiac cell). Therefore, in some embodiments, the AAV expression cassette disclosed herein comprises a promoter that expresses a transgene at a higher level in cardiac cells than the promoter expresses a transgene in non-cardiac cells. In some embodiments, the promoter expresses the transgene in cardiac cells at a level that is at least about 1.2 times higher than the level at which the transgene is expressed in non-cardiac cells (e.g., about 1.5 times, about 2 times, about 2.5 times, about 3 times, about 3.5 times, about 4 times, about 4.5 times, about 5 times, about 5.5 times, about 6 times, about 6.5 times, about 7 times, about 7.5 times, about 8 times, about 8.5 times, about 9 times, about 9.5 times, about 10 times, about 15 times, about 20 times, about 30 times, about 40 times, about 50 times, about 60 times, about 70 times, about 80 times, about 90 times, or about 100 times, including all values and subranges therebetween).
[0091] In some embodiments, the promoter may include a nucleic acid sequence derived from an endogenous promoter and / or an endogenous enhancer, such as an endogenous promoter and / or an endogenous enhancer of a gene expressed at a higher level in cardiac tissue compared to non-cardiac tissue. In some embodiments, the promoter is a promoter of the TNNT2 gene encoding cardiac troponin T, and is referred to herein as cardiac troponin T (TNNT2) promoter. In some embodiments, the TNNT2 promoter includes a nucleic acid sequence derived from: (i) human TNNT2 promoter, (ii) chicken TNNT2 promoter, (iii) mouse TNNT2 promoter, or (iv) any combination thereof. In some embodiments, the TNNT2 promoter includes human TNNT2 promoter. In some embodiments, the promoter comprises a sequence of SEQ ID NO:4, or a sequence that is at least 70% identical thereto (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identical thereto, including all values and subranges therebetween).
[0092] In some embodiments, the AAV expression cassette described herein further comprises an enhancer. The enhancer can be, for example, a CMV enhancer. In some embodiments, the enhancer comprises a sequence of SEQ ID NO: 16 or a sequence having at least 70% identity thereto (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identity thereto, including all values and subranges therebetween).
[0093] In some embodiments, the promoter further comprises a nucleic acid sequence derived from any one or more of the following promoters: HMG-COA reductase promoter; sterol regulatory element 1 (SRE-1); phosphoenolpyruvate carboxykinase (PEPCK) promoter; human C-reactive protein (CRP) promoter; human glucokinase promoter; cholesterol 7-alpha hydroxylase (CYP-7) promoter; β-galactosidase alpha-2,6 sialyltransferase promoter; insulin-like growth factor binding protein (IGFBP-1) promoter; aldolase B promoter; human transferrin promoter; type I collagen promoter; prostatic acid phosphatase (PAP) promoter; prostate secretory protein 94 (PSP 94) promoter; prostate-specific antigen complex promoter; human glandular kallikrein gene promoter (hgt-1); myocyte-specific enhancer binding factor MEF-2; muscle creatine kinase promoter; pancreatitis-associated protein promoter (PAP); elastase 1 transcription enhancer; pancreatic specific amylase and elastase enhancer promoter; pancreatic cholesterol esterase gene promoter; uteroglobin promoter; cholesterol side chain cleavage (SCC) promoter; gamma-gamma enolase (neuron-specific enolase, NSE) promoter; neurofilament heavy chain (NF-H) promoter; human CGL-1 / granzyme B promoter; terminal deoxytransferase (TdT), λ5, VpreB and lck (lymphocyte-specific tyrosine protein kinase p561ck) promoter; human CD2 promoter and its 3' transcription enhancer; human NK and T cell-specific activation (NKG5) promoter; pp60c-src tyrosine kinase promoter; organ-specific neoantigens (OSN), mw 40kDa (p40) promoter; colon specific antigen-P promoter; human alpha-lactalbumin promoter; phosphoenolpyruvate carboxykinase (PEPCK) promoter, HER2 / neu promoter, casein promoter, IgG promoter, chorionic embryonic antigen promoter, elastase promoter, porphobilinogen deaminase promoter, insulin promoter, growth hormone factor promoter, tyrosine hydroxylase promoter, albumin promoter, alpha-fetoprotein promoter, acetylcholine receptor promoter, alcohol dehydrogenase promoter, alpha or beta globin promoter, T cell receptor promoter, osteocalcin promoter, IL-2 promoter, IL-2 receptor promoter, whey (wap) promoter and MHC class II promoter. In some embodiments, the AAV expression cassette disclosed herein further comprises a nucleic acid sequence derived from any one or more promoters, enhancers and / or other sequences described in U.S. Pat. No. 8,708,948 B2, U.S. Pat. No. 9,1385,96 B2, U.S. Pat. No. 10,286,085 B2, and U.S. Pat. No. US8538520 B2, the contents of each of which are incorporated herein by reference in their entirety.
[0094] (iii) Arrhythmogenic cardiomyopathy-related genes
[0095] As used herein, "arrhythmogenic cardiomyopathy-associated gene" refers to any gene in a subject with arrhythmogenic cardiomyopathy that can be targeted by gene therapy to alleviate at least one symptom of arrhythmogenic cardiomyopathy. In some embodiments, the protein level encoded by the arrhythmogenic cardiomyopathy-associated gene is reduced or undetectable in a subject with arrhythmogenic cardiomyopathy. In some embodiments, the arrhythmogenic cardiomyopathy-associated gene encodes a protein that contributes to normal cardiac function. In some embodiments, the arrhythmogenic cardiomyopathy-associated gene encodes a protein that contributes to normal myocardial function. In some embodiments, the arrhythmogenic cardiomyopathy-associated gene encodes a protein that contributes to the normal function of desmosomes in cells containing desmosomes (e.g., cardiac cells and epithelial cells).
[0096] In some embodiments, a mutation in an arrhythmogenic cardiomyopathy-related gene (e.g., PKP2 gene) is present in a subject suffering from arrhythmogenic cardiomyopathy. In some embodiments, a loss of function or haploid deficiency of an arrhythmogenic cardiomyopathy-related gene (e.g., PKP2 gene) is present in a subject suffering from arrhythmogenic cardiomyopathy. In some embodiments, a mutation in an arrhythmogenic cardiomyopathy-related gene or a loss of function of an arrhythmogenic cardiomyopathy-related gene is associated with arrhythmogenic cardiomyopathy, promoting or causing arrhythmogenic cardiomyopathy. The mutation type in an arrhythmogenic cardiomyopathy-related gene (e.g., PKP2 gene) is not limited, and can be insertion, deletion, duplication and / or substitution. In some embodiments, the mutation in the PKP2 gene is any PKP2 mutation identified in a patient suffering from arrhythmogenic cardiomyopathy. For example, the mutation of the PKP2 gene is selected from one or more PKP2 gene mutations described in: Gerull B et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004 Nov; 36(11): 1162-4, which is incorporated herein by reference in its entirety for all purposes.
[0097] The present disclosure provides an AAV expression cassette comprising an arrhythmogenic cardiomyopathy-related gene. In some embodiments, the AAV expression cassette comprises an arrhythmogenic cardiomyopathy-related gene, and the gene encodes a protein, including a therapeutic (e.g., for medical or veterinary use) or an immunogenic (e.g., for a vaccine) polypeptide. In some embodiments, the AAV expression cassette comprises a mammalian arrhythmogenic cardiomyopathy-related gene. In some embodiments, the AAV expression cassette comprises a human arrhythmogenic cardiomyopathy-related gene. In some embodiments, the AAV expression cassette comprises an arrhythmogenic cardiomyopathy-related gene encoding desmosome plaque phycin protein-2.
[0098] In some embodiments, the transgene encodes desmoplakin protein-2. In some embodiments, the transgene encodes isoform 2a of human desmoplakin protein-2. In some embodiments, isoform 2a of human desmoplakin protein-2 comprises an amino acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identity to SEQ ID NO: 1, including all values and subranges therebetween). In some embodiments, isoform 2a of human desmoplakin protein-2 comprises the amino acid sequence of SEQ ID NO: 1 or a sequence having at least 90% identity thereto.
[0099] In some embodiments, the transgenic gene encodes RNA transcript variant 2a of the PKP2 gene. In some embodiments, the transgenic gene comprises a nucleic acid sequence with at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identity, including all values and subranges therebetween) to SEQ ID NO: 2. In some embodiments, the transgenic gene comprises a nucleic acid sequence of SEQ ID NO: 2 or a sequence with at least 90% identity thereto.
[0100] In some embodiments, the transgene encodes isoform 2b of human desmoplakin protein-2. In some embodiments, isoform 2b of human desmoplakin protein-2 comprises an amino acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identity to SEQ ID NO: 3, including all values and subranges therebetween). In some embodiments, isoform 2b of human desmoplakin protein-2 comprises an amino acid sequence of SEQ ID NO: 3 or a sequence having at least 90% identity thereto. In some embodiments, the transgene encodes RNA transcript variant 2b of a PKP2 gene. In some embodiments, the PKP2 gene is a human PKP2 gene.
[0101] In some embodiments, the AAV expression cassette comprises a Kozak sequence. The Kozak sequence is a nucleic acid sequence that acts as a protein translation start site in many eukaryotic mRNA transcripts. In some embodiments, the Kozak sequence overlaps with the start codon. In some embodiments, the Kozak sequence comprises a nucleic acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identity, including all values and subranges therebetween) with a nucleic acid sequence of SEQ ID NO: 10 or acagccacc. In some embodiments, the Kozak sequence comprises a nucleic acid sequence of SEQ ID NO: 10 or a sequence having at least 90% identity thereto; or a nucleic acid sequence of acagccacc or a sequence having at least 90% identity thereto.
[0102] (iv) Polyadenylation (PolyA) signal
[0103] The polyadenylation signal is a nucleotide sequence found in almost all mammalian genes and controls the addition of a string of approximately 200 adenosine residues (the poly(A) tail) to the 3' end of the gene transcript. The poly(A) tail contributes to mRNA stability, and mRNAs lacking the poly(A) tail are rapidly degraded. There is also evidence that the presence of the poly(A) tail actively contributes to the translatability of mRNA by affecting translation initiation.
[0104] In some embodiments, the AAV expression cassette of the present disclosure comprises a polyadenylation signal. The polyadenylation signal can be selected from the polyadenylation signal of simian virus 40 (SV40), rabbit beta globin (rBG), alpha globin, beta globin, human collagen, human growth hormone (hGH), polyoma virus, human growth hormone (hGH) and bovine growth hormone (bGH).
[0105] In some embodiments, the AAV expression cassette comprises a bGH polyadenylation signal. In some embodiments, the bGH polyadenylation signal comprises a nucleic acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity, including all values and subranges therebetween) to the nucleic acid sequence of SEQ ID NO: 8. In some embodiments, the bGH polyadenylation signal comprises a nucleic acid sequence of SEQ ID NO: 8 or a sequence having at least 90% identity thereto.
[0106] In some embodiments, the polyadenylation signal is an SV40 polyadenylation signal. In some embodiments, the polyadenylation signal is an rBG polyadenylation signal. In some embodiments, the polyadenylation signal comprises the sequence of SEQ ID NO: 17 or SEQ ID NO: 18. In some embodiments, the polyadenylation signal comprises a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of SEQ ID NO: 17 or SEQ ID NO: 18.
[0107] (v) Filling sequence
[0108] AAV vectors typically accept DNA inserts of a defined size range, typically from about 4 kb to about 5.2 kb, or slightly larger. Thus, for shorter sequences, it may be necessary to include additional nucleic acid in the insert to achieve the desired length acceptable to the AAV vector. Thus, in some embodiments, the AAV expression cassettes of the present disclosure may include a stuffer sequence. The stuffer sequence can be, for example, a sequence between 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-75, 75-100, 100-150, 150-200, 200-250, 250-300, 300-400, 400-500, 500-750, 750-1,000, 1,000-1,500, 1,500-2,000, 2,000-2,500, 2,500-3,000, 3,000-3,500, 3,500-4,000, 4,000-4,500, or 4,500-5,000 or more nucleotides in length. The stuffer sequence can be located at any desired position in the cassette so that it does not hinder the function or activity of the vector.
[0109] In some embodiments, the AAV box comprises at least one stuffer sequence. In some embodiments, the stuffer sequence comprises a nucleic acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity to the nucleic acid sequence of SEQ ID NO: 9, including all values and subranges therebetween). In some embodiments, the stuffer sequence comprises a nucleic acid sequence of SEQ ID NO: 9 or a sequence having at least 90% identity thereto. In some embodiments, the stuffer sequence comprises a nucleic acid sequence of SEQ ID NO: 9 or a portion thereof. In some embodiments, the stuffer sequence comprises a nucleic acid sequence of SEQ ID NO: 9 or a portion thereof (e.g., a 500 nucleotide long portion) of a sequence having at least 90% identity thereto.
[0110] (vi) Intron sequences
[0111] In some embodiments, the AAV expression cassettes of the present disclosure may comprise an intron sequence. In some embodiments, the inclusion of an intron sequence enhances expression compared to expression in the absence of the intron sequence.
[0112] In some embodiments, the intron sequence is a hybrid or chimeric sequence. In some embodiments, the intron sequence is separated from or derived from the intron sequence of one or more of SV40, β-globin, chicken β-actin, parvovirus of mice (MVM), factor IX and / or human IgG (heavy chain or light chain). In some embodiments, the intron sequence is chimeric. In some embodiments, the intron sequence comprises a nucleic acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or 100% identity with the nucleic acid sequence of SEQ ID NO: 7, including all values and subranges therebetween). In some embodiments, the intron sequence comprises a sequence of SEQ ID NO: 7 or a sequence having at least 90% identity therewith. In some embodiments, the intron sequence comprises a sequence of SEQ ID NO: 7.
[0113] AAV production method
[0114] The AAV expression cassettes described herein can be integrated into a vector (e.g., a plasmid or bacmid) using standard molecular biology techniques. The present disclosure provides a vector comprising any of the AAV expression cassettes described herein. The vector (e.g., a plasmid or bacmid) can further comprise one or more genetic elements used during AAV production, including, for example, AAV rep and cap genes and helper viral protein sequences.
[0115] The AAV expression cassettes described herein and vectors (eg, plasmids) comprising the AAV expression cassettes can be used to produce recombinant AAV vectors.
[0116] The present disclosure provides a method for producing a recombinant AAV vector, comprising contacting an AAV production cell (e.g., HEK293 cell) with an AAV expression cassette or vector (e.g., plasmid) of the present disclosure. The present disclosure further provides a cell comprising any AAV expression cassette or vector disclosed herein. In some embodiments, the method further comprises contacting the AAV production cell with one or more additional plasmids encoding, for example, AAV rep and cap genes and helper virus protein sequences. In some embodiments, the method for producing a recombinant AAV vector comprises contacting an AAV production cell (e.g., an insect cell, such as an Sf9 cell) with at least one insect cell compatible vector comprising an AAV expression cassette of the present disclosure. An "insect cell compatible vector" is any compound or preparation (biological or chemical) that helps transform or transfect insect cells with nucleic acids. In some embodiments, the insect cell compatible vector is a baculovirus vector. In some embodiments, the method further comprises maintaining the insect cell under conditions for producing AAV.
[0117] The present disclosure provides a recombinant AAV vector produced using any of the methods disclosed herein. The recombinant AAV vector produced can be any serotype, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV. In some embodiments, the recombinant AAV vector produced may include one or more amino acid modifications (e.g., substitutions and / or deletions) compared to the native AAV capsid. For example, the recombinant AAV vector can be a modified AAV vector derived from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV and bovine AAV. In some embodiments, the recombinant AAV vector is a single-stranded AAV (ssAAV). In some embodiments, the recombinant AAV vector is a self-complementary AAV (scAAV).
[0118] In some embodiments, the AAV vector comprises a capsid protein of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV. In some embodiments, the AAV vector comprises a capsid protein having one or more substitutions or mutations compared to the wild-type AAV capsid protein. The recombinant AAV vector disclosed herein can be used to transduce a target cell with a transgenic sequence, for example, by contacting the recombinant AAV vector with the target cell.
[0119] In some embodiments, the AAV vector comprises a capsid protein comprising: an amino acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity to SEQ ID NO: 13, including all values and subranges therebetween). In some embodiments, in some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 13.
[0120] In some embodiments, the AAV vector comprises a capsid protein comprising: an amino acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity to SEQ ID NO: 14. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 14.
[0121] In some embodiments, the AAV vector comprises a capsid protein comprising: an amino acid sequence having at least 70% identity (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identity to SEQ ID NO: 15. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15 or a sequence having at least 90% identity thereto. In some embodiments, the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15.
[0122] In some embodiments, the AAV vector comprises a capsid protein comprising: (i) an amino acid sequence of SEQ ID NO: 13, or a sequence having at least 90% identity thereto, or (ii) an amino acid sequence of SEQ ID NO: 14, or a sequence having at least 90% identity thereto, or (iii) an amino acid sequence of SEQ ID NO: 15, or a sequence having at least 90% identity thereto.
[0123] Methods of expression and treatment
[0124] The present disclosure provides compositions, which include any one of nucleic acid, AAV expression cassette, plasmid, cell or recombinant AAV vector disclosed herein. In some embodiments, compositions disclosed herein include at least one pharmaceutically acceptable carrier, excipient and / or vehicle, such as solvent, buffer, solution, dispersion medium, coating, antibacterial and antifungal agents, isotonic agents and absorption delay agents. In some embodiments, pharmaceutically acceptable carriers, excipients and / or vehicles may include saline, buffered saline, glucose, water, glycerol, sterile isotonic water buffer and combinations thereof. In some embodiments, pharmaceutically acceptable carriers, excipients and / or vehicles include phosphate buffered saline, sterile saline, lactose, sucrose, calcium phosphate, dextran, agar, pectin, peanut oil, sesame oil, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, saccharin sodium, cellulose, magnesium carbonate, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) or a suitable mixture thereof. In some embodiments, the compositions disclosed herein further comprise minor amounts of emulsifiers or wetting agents, or pH buffering agents.
[0125] In some embodiments, the compositions disclosed herein further comprise other conventional pharmaceutical ingredients, such as preservatives or chemical stabilizers, such as chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerol, phenol, p-chlorophenol or albumin. In some embodiments, the compositions disclosed herein may further comprise antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid or thimerosal; isotonic agents, such as sugars or sodium chloride, and / or agents that delay absorption, such as aluminum monostearate and gelatin.
[0126] The present disclosure provides a method for expressing an ACM-associated transgene in a cell, comprising: contacting the cell with any one of the nucleic acid molecules, plasmids, cells, recombinant AAV vectors or compositions disclosed herein, thereby expressing the ACM-associated transgene in the cell.
[0127] The present disclosure provides a method for expressing an ACM-associated transgene in a tissue, comprising: contacting the tissue with any one of the nucleic acid molecules, plasmids, cells, recombinant AAV vectors or compositions disclosed herein, thereby expressing the ACM-associated transgene in the tissue. In some embodiments, the tissue comprises at least one cell and at least one desmosomal junction.
[0128] In some embodiments, the cell is a cardiac cell, an endothelial cell, a skin cell, a bladder cell, or a gastrointestinal mucosal cell. In some embodiments, the cell is a cardiac cell. In some embodiments, the cell is a dividing cell, such as a cultured cell in a cell culture. In some embodiments, the cell is a non-dividing cell. In some embodiments, the arrhythmogenic cardiomyopathy-related gene is delivered to an in vitro cell, for example to produce an arrhythmogenic cardiomyopathy-related polypeptide in vitro, or for ex vivo gene therapy.
[0129] In some embodiments, the contacting step is performed in vitro, ex vivo, or in vivo. In some embodiments, the contacting step is performed in vivo in a subject in need thereof. In some embodiments, the contacting step comprises administering to the subject a therapeutically effective amount of a nucleic acid molecule, a plasmid, a recombinant AAV vector, or a composition. In some embodiments, the subject suffers from or is at risk of developing arrhythmogenic cardiomyopathy.
[0130] The present disclosure provides a method for treating arrhythmogenic cardiomyopathy in a subject in need thereof, comprising administering to the subject any one of a therapeutically effective amount of nucleic acid molecules, plasmids, cells, recombinant AAV vectors or compositions disclosed herein, thereby treating the subject's arrhythmogenic cardiomyopathy. In some embodiments, the subject suffers from arrhythmogenic cardiomyopathy or is at risk of developing arrhythmogenic cardiomyopathy. In some embodiments, arrhythmogenic cardiomyopathy is arrhythmogenic right ventricular cardiomyopathy. In some embodiments, arrhythmogenic cardiomyopathy is associated with genetic changes, promoted by genetic changes or caused by genetic changes. In some embodiments, genetic changes include one or more genetic changes (e.g., one or more deletions, insertions, duplications and / or substitutions) of the PKP2 gene compared to the wild-type PKP2 gene, and / or changes in the expression and / or activity of the PKP2 protein compared to the wild-type PKP2 protein. In some embodiments, mutations in the PKP2 gene cause PKP2 haploinsufficiency. In some embodiments, the subject at risk of developing arrhythmogenic cardiomyopathy is a newborn identified as carrying a PKP2 gene mutation. In some embodiments, an arrhythmogenic cardiomyopathy-related gene (e.g., PKP2) is targeted by gene therapy to increase its expression and / or function.
[0131] In some embodiments, the method comprises reducing the severity of arrhythmogenic cardiomyopathy; delaying its onset or progression; and / or eliminating its symptoms. In some embodiments, symptoms of arrhythmogenic cardiomyopathy include: (a) reentrant ventricular tachycardia, (b) syncope, (c) sudden death, or (d) any combination thereof. In some embodiments, arrhythmogenic cardiomyopathy is associated with: (a) reduced mechanical stability between cardiomyocytes of the subject, (b) disrupted gap junctions in the subject's cardiac tissue, (c) reduced sodium currents in the subject's cardiac tissue, (d) fibrosis of the right ventricular myocardium, or (e) any combination thereof.
[0132] In some embodiments, the method comprises increasing mechanical stability between cardiomyocytes of the subject. In some embodiments, the method comprises improving the function of gap junctions in cardiac tissue of the subject. In some embodiments, the method comprises increasing sodium currents in cardiac tissue of the subject. In some embodiments, the method comprises reducing fibrosis of right ventricular myocardium of the subject.
[0133] In some embodiments, the method includes increasing the left ventricular ejection fraction of the heart compared to a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method includes increasing the left ventricular ejection fraction of the heart compared to the left ventricular ejection fraction of the subject's heart before administering a therapeutically effective amount. In some embodiments, the method includes increasing the left ventricular ejection fraction of the heart to a value in the range of about 30% to about 80%, for example, about 35%, about 40%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75% or about 80%, including sub-ranges and values located therebetween. In some embodiments, the method includes increasing the left ventricular ejection fraction of the heart to about 60%.
[0134] In some embodiments, the method comprises reducing the right ventricular area of the heart compared to a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises reducing the right ventricular area of the heart compared to the right ventricular area of the subject's heart before administration of the therapeutically effective amount.
[0135] In some embodiments, the method includes extending the survival of the subject compared to a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method includes extending the survival of the subject compared to the expected survival of the subject before the administration of a therapeutically effective amount. In some embodiments, the method includes extending the survival of the subject by about 3 months to about 50 years (e.g., about 6 months, about 1 year, about 5 years, about 10 years, about 15 years, about 20 years, about 25 years, about 30 years, about 35 years, about 40 years, about 45 years, about 50 years, including sub-ranges and values therebetween) compared to: (i) a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount, or (ii) the expected survival of the subject before the administration of a therapeutically effective amount. The dosage of the recombinant AAV vector to be administered to a subject depends on the mode of administration, the disease or condition to be treated and / or prevented, the condition of the individual subject, the particular viral vector or capsid, the nucleic acid to be delivered, etc., and can be determined in a routine manner. An exemplary dosage for achieving a therapeutic effect is at least about 10 5 , about 10 6 , about 10 7 , about 10 8 , about 10 9 , about 10 10 , about 10 11 , about 10 12 , about 10 13 , about 10 14 , about 10 15 transduction units, optionally about 10 8 to about 10 13 The titer of transducing units.
[0136] In some embodiments, the method comprises increasing the ejection fraction of the subject compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises increasing the ejection fraction of the subject compared to the ejection fraction of the subject before administration of the therapeutically effective amount.
[0137] In some embodiments, the method comprises increasing the subject's stroke volume compared to a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises increasing the subject's stroke volume compared to the subject's stroke volume prior to administration of the therapeutically effective amount.
[0138] In some embodiments, the method comprises increasing the cardiac output of the subject compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises increasing the cardiac output of the subject compared to the cardiac output of the subject prior to administration of the therapeutically effective amount.
[0139] In some embodiments, the method comprises increasing the fractional shortening percentage of the subject compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises increasing the fractional shortening percentage of the subject compared to the fractional shortening percentage of the subject before administering a therapeutically effective amount.
[0140] In some embodiments, the method comprises increasing the left ventricular outflow tract velocity time integral of the subject compared to a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises increasing the left ventricular outflow tract velocity time integral of the subject compared to the left ventricular outflow tract velocity time integral of the subject prior to administration of the therapeutically effective amount.
[0141] In some embodiments, the method comprises reducing the left ventricular volume of the subject compared to a control subject with arrhythmogenic cardiomyopathy, wherein the control subject has not been administered a therapeutically effective amount. In some embodiments, the method comprises reducing the left ventricular volume of the subject compared to the left ventricular volume of the subject before administration of the therapeutically effective amount.
[0142] In certain embodiments, more than one administration (eg, two, three, four, or more administrations) may be used to achieve desired gene expression levels at various time intervals (eg, daily, weekly, monthly, yearly, etc.).
[0143] In some embodiments, the subject is a human subject. In some embodiments, the nucleic acid molecule, plasmid, cell, recombinant AAV vector or composition is administered to the cardiac tissue of the subject. In some embodiments, the nucleic acid molecule, plasmid, cell, recombinant AAV vector or composition is administered to the left atrium, right atrium, left ventricle, right ventricle and / or septum. In some embodiments, the nucleic acid molecule, plasmid, cell, recombinant AAV vector or composition is administered to the subject by intravenous administration, intra-arterial administration, intra-aortic administration, direct cardiac injection, coronary artery perfusion, or any combination thereof.
[0144] Other modes of administration include oral, transmucosal, intrathecal, transdermal, parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular [including administration to bones, diaphragm and / or myocardium], transdermal, intrapleural, intracerebral and intraarticular), intralymphatic, etc., and direct tissue or organ injection (e.g., injection to the liver, skeletal muscle, myocardium, diaphragm or brain). Delivery to target tissues can also be achieved by delivering a reservoir containing viral vectors and / or capsids. In representative embodiments, a reservoir containing viral vectors and / or capsids is implanted into bone, heart and / or diaphragm tissue, or the tissue can be contacted with a membrane or other matrix containing viral vectors and / or capsids.
[0145] In some embodiments, the methods disclosed herein may include administering to a subject a therapeutically effective amount of any of the nucleic acids, AAV expression cassettes, plasmids, cells, recombinant AAV vectors, or compositions disclosed herein, in combination with one or more secondary therapies for arrhythmogenic cardiomyopathy. In some embodiments, the methods disclosed herein for treating at least one symptom of arrhythmogenic cardiomyopathy in a subject and / or delaying its onset may further include administering one or more secondary therapies for arrhythmogenic cardiomyopathy. In some embodiments, secondary treatment includes administering a drug, such as a beta blocker or amiodarone, an implantable cardioverter-defibrillator (ICD), catheter ablation, or any combination thereof. Non-limiting examples of beta blockers include acebutolol, atenolol, bisoprolol, metoprolol, nadolol, nebivolol, and propranolol.
[0146] As used herein, the term "combined administration" is understood to mean that during the course of a subject suffering from a disease (e.g., arrhythmogenic cardiomyopathy), two (or more) different treatments are delivered to the subject so that the effects of the treatments on the patient overlap at a certain point in time. In certain embodiments, when the delivery of the second treatment begins, the delivery of one treatment is still ongoing, so there is an overlap in administration. This is sometimes referred to as "simultaneous" or "concurrent" delivery in this article. In other embodiments, the delivery of one treatment ends before the delivery of another treatment begins, which can be referred to as "sequential" delivery.
[0147] In some embodiments, the treatments are more effective due to combined administration. For example, the second treatment is more effective, an equivalent effect can be seen with less of the second treatment, or the second treatment relieves symptoms to a greater extent than if the second treatment were given without the first treatment, or a similar situation can be seen with the first treatment. The effects of the two treatments can be partially additive, fully additive, or greater than additive (synergistic).
[0148] All articles, publications and patents cited in this specification are incorporated herein by reference, as if each individual article, publication or patent was specifically and individually indicated to be incorporated herein by reference, and are incorporated herein by reference to disclose and describe the methods and / or materials related to the cited publications. However, the reference to any reference, article, publication, patent, patent publication and patent application cited herein does not and should not be taken as an admission or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.
[0149] It is specifically contemplated that the various features described herein can be used in any combination unless the context dictates otherwise.
[0150] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0151] It should be understood that the above description and the following embodiments are intended to illustrate rather than limit the scope of the present invention. Other aspects, advantages and modifications within the scope of the present invention will be apparent to those skilled in the art to which the present invention belongs.
[0152] Example
[0153] The following examples are included herein for illustrative purposes only and are not intended to be limiting.
[0154] Example 1: Preparation of AAV expression cassettes and recombinant AAV vectors in mammalian cells
[0155] Standard cloning techniques were used to generate an AAV expression cassette containing the following elements: (i) 5'AAV ITR of SEQ ID NO:5, (ii) cardiac troponin T (TNNT2) promoter of SEQ ID NO:4; (iii) human β-globin (hBG) intron of SEQ ID NO:7; (iv) human PKP2a transgene sequence of SEQ ID NO:2; (v) bovine growth hormone (bGH) polyA tail of SEQ ID NO:8; and (vi) 3'AAV ITR of SEQ ID NO:6. See Figure 1 , which shows a schematic diagram of an AAV cassette. The AAV cassette comprises the sequence of SEQ ID NO:12.
[0156] Incorporate the AAV expression cassette into the plasmid ( Figure 2 ) and use a suitable transfection reagent (e.g. Lipofectamine TM) together with the Rep / Cap plasmid encoding the Rep and Cap genes, and the helper plasmids (E4, E2a and VA) containing various helper sequences required for AAV production, are transfected into virus-producing cells (e.g., HEK293). After incubation at 37°C for a predetermined period of time, AAV particles are collected from the culture medium, or the cells are lysed to release AAV particles. The AAV particles are then purified, titrated, and stored at -80°C for later use.
[0157] In the manner described above, AAV particles comprising the disclosed AAV expression cassette of SEQ ID NO: 12 and a capsid protein having the amino acid sequence of SEQ ID NO: 13 were produced, and these AAV particles are referred to herein as "AAV.STRV47-hTNNT2.PKP2a".
[0158] Similarly, AAV particles were generated comprising the disclosed AAV expression cassette of SEQ ID NO: 12 and a capsid protein having the amino acid sequence of SEQ ID NO: 14 (referred to herein as "AAV.STRV5-hTNNT2.PKP2a").
[0159] Finally, AAV particles comprising the disclosed AAV expression cassette of SEQ ID NO: 12 and a capsid protein having the amino acid sequence of SEQ ID NO: 15 were also generated (referred to herein as "AAV.STRV84-hTNNT2.PKP2a").
[0160] Example 2: Increased PKP2 mRNA and protein in cardiomyocytes after treatment with AAV.STRV47-hTNNT2.PKP2a Quality Level
[0161] Healthy normal human iPSC-derived cardiomyocytes were treated with 50K MOI of AAV.STRV47-hTNNT2.PKP2a 3 after plating. After 7 days of treatment, PKP2a mRNA and PKP2a protein expression were evaluated by RT-qPCR and Western blot, respectively. 1 μM antisense oligonucleotides (ASO) for PKP2 were used as controls to knock out (KD) PKP2. For mRNA expression, the manufacturer's protocol (Invitrogen, catalog number A35377) was followed to collect RNA using a cell-CT kit. RT-qPCR was performed to measure mRNA expression using a TaqMan probe (Hs00428040_m1) for PKP2 and a housekeeping gene UBC (Hs00824723_m1).
[0162] like Figure 3AAs shown, the results showed that after knocking down PKP2 using antisense oligonucleotides, PKP2 mRNA expression was reduced. However, after transducing cells with AAV.STRV47-hTNNT2.PKP2a, PKP2 mRNA increased several fold compared to wild-type cells. These results indicate that treatment of cardiomyocytes with AAV.STRV47-hTNNT2.PKP2a leads to increased PKP2 mRNA expression.
[0163] For protein expression, lyse the plate with 300ul 1x RIPA plus protease inhibitors. Scrape the plate and shake in the refrigerator for 15 minutes. Collect the cell lysate and centrifuge for 10 minutes at 4°C. Collect the supernatant. Dilute the protein lysate with 4x LiCOR sample buffer and load the sample on a Tris / glycine 20-4% SDS-page gel and run until the dye front reaches the bottom of the gel. Transfer the gel to PDVF using the multiMW setting on the BioRad Trans-Blot Turbo system following the manufacturer's protocol. Block the membrane with LiCOR blocking buffer for 30 minutes at room temperature and then incubate with antibodies against PKP2 (American Research Products, Inc.), cTnT (Abcam ab45932), or β-tubulin at a dilution of 1:1000.
[0164] like Figure 3B As shown in Figure 3C Quantification in the middle, the results showed that after knocking down PKP2 using antisense oligonucleotides, PKP2 protein expression was reduced. However, after transducing cells with AAV.STRV47-hTNNT2.PKP2a, PKP2 protein was significantly increased compared with wild-type cells. These results indicate that treatment of cardiomyocytes with AAV.STRV47-hTNNT2.PKP2a leads to increased PKP2 protein expression.
[0165] Example 3: AAV.STRV5-hTNNT2.PKP2a can rescue the iPSC PKP2-KO cardiomyocyte model PKP2a expression level
[0166] Human PKP1 knockout iPSC cells were generated by homozygous insertion of premature stop codons (S70X) mediated by CRISPR / Cas9. The cells were then differentiated into cardiomyocytes. The method for producing cardiomyocytes is described in Burridge et al., 2014, Nat Methods. August 2014; 11 (8): 855-60; and Lian et al., 2012, Proc Natl Acad Sci USA. July 3, 2012; 109 (27): E1848-57, the contents of each of which are incorporated herein by reference in their entirety. Successful differentiation leads to the expression of cardiomyocyte marker TNNT2 and spontaneously beating cells.
[0167] Notably, transduction of iPSC PKP2-KO cardiomyocytes with AAV.STRV5-hTNNT2.PKP2a resulted in restoration of PKP2a expression to wild-type levels 10 days after transduction ( Figure 4A and 4B ). PKP2a expression was then examined by immunofluorescence, and correct plasma membrane localization of PKP2a expressed using AAV was observed in transduced iPSC PKP2-KO cardiomyocytes, similar to the wild-type. Figure 4C .
[0168] Knockdown of PKP2a protein also affects the electrical phenotype of human iPSC cardiomyocytes. Calcium transients were measured in spontaneously beating confluent cardiomyocyte cultures. A transduction control (encoding GFP) was included to account for any effects of transduction. Calcium recordings in PKP2-KO cardiomyocytes showed that calcium transients were expressed early after the transient (at Figure 5B and 5C In iPSC PKP2-KO cardiomyocytes transduced with AAV.STRV5-hTNNT2.PKP2a, restoration of PKP2a expression as described above resulted in normal calcium transients similar to those seen in WT iPSC cardiomyocytes ( Figure 5A and 5D ).
[0169] Together, these data demonstrate that AAV.STRV5-hTNNT2.PKP2a transduction is able to restore PKP2 expression in iPSC PKP2-KO cardiomyocytes, thereby significantly rescuing the electrical phenotype of PKP2-deficient cardiomyocytes.
[0170] Example 4: Expression of PKP2 in wild-type mice after treatment with AAV.STRV47-hTNNT2.PKP2a
[0171] Wild-type mice at 11 weeks of age were used for two groups (control group and treatment group, n=4 in both groups) of in vivo preliminary studies. See Table A. The treatment group was given 5e13vg / kg of AAV.STRV47-hTNNT2.PKP2a (total volume of 150μL, total VG dose of 1.25e12) by tail vein IV injection. 21 days after administration, the expression of the human PKP2 gene in mouse heart tissue of both groups of mice was evaluated using molecular techniques (including qPCR, RT-qPCR and Western blot).
[0172] Table A:
[0173]
[0174] To extract DNA, 50 mg of tissue was placed in a tube containing stainless steel beads and 300 μL TE buffer and 30 μL 20 mg / mL proteinase K solution and homogenized. The samples were then incubated at 56°C for 20 minutes and then DNA was extracted using the MaxwellRSC Tissue DNA Kit (Promega, catalog number AS1610) on a Maxwell RSC 48 instrument according to the manufacturer's protocol. DNA concentration and A260 / A280 were measured using NanoDrop. qPCR was performed on a QS3 instrument (Thermo) using custom PKP2 primers and probes. Fig. 6A It was shown that the PKP2a transgene was detectable in the heart tissue of mice treated with the AAV.STRV47-hTNNT2.PKP2a vector.
[0175] For RNA extraction, 10-20 mg of tissue was placed in a tube containing stainless steel beads and 250 μL of homogenization buffer and homogenized with a bead blaster. The samples were incubated at 70°C for 2 minutes. RNA was extracted using the Maxwell RSC Tissue RNA Kit (Promega, catalog number AS1340) on a Maxwell RSC 48 instrument according to the manufacturer's protocol. RNA concentration and A260 / A280 were measured using NanoDrop. For RT-qPCR, DNase I was added to the samples and incubated at 37°C for 2 minutes. The samples were then diluted 1:20 and reverse transcriptase reactions were performed with dNTP mix and SuperScript IV reverse transcriptase to generate cDNA. qPCR was performed on a QS3 instrument (Thermo) using custom PKP2 primers and probes and normalized to the housekeeping gene mouse GAPDH. Figure 6B It was shown that PKP2a mRNA was detectable in the heart tissue of mice treated with the AAV.STRV47-hTNNT2.PKP2a vector.
[0176] For protein extraction, 50-100 mg of tissue samples were homogenized in PBS and protease inhibitors (Boston Bioproducts, catalog number BP-475) using a bead blaster. Figure 6C As shown, proteins were detected using the Jess automated western blotting system with anti-PKP2 antibody (1:100) from American Research Products, Inc. (Cat. No. 03-651101). Analyses were performed using the Jess software Fig.6D Quantification shown in and normalized to the mean of PBS control. The results show that PKP2a protein is readily detected in cardiac tissue of mice treated with AAV.STRV47-hTNNT2.PKP2a vector.
[0177] Example 5: Cardiac-specific expression of AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a PKP2 expression in a PKP2 knockout mouse model ("PKP2-cKO") results in prolonged survival
[0178] Gene targeting constructs were generated by introducing two loxP sites flanking mouse Pkp2 exons 2 and 3, followed by a neomycin resistance gene. The linearized construct was electroporated into mouse (C57BL / 6) embryonic stem cells (ES), followed by neomycin selection of positive ES cell clones. Positive clones were injected into mouse blastocysts and then injected into foster mice. The resulting F1 heterozygous mice were hybridized with mice expressing flippase to excise the neomycin resistance gene. Mice homozygous for the Pkp2 targeting allele (Pkp2 fl / fl) were hybridized with mice expressing Cre recombinase under the control of a cardiomyocyte-specific promoter (αMHC-Cre-ER(T2)), and the Cre recombinase was fused to a mutant form of the human estrogen receptor ligand binding domain. After Pkp2 fl / fl, αMHC-Cre-ER(T2) mice were treated with tamoxifen, Pkp2 exons 2 and 3 were specifically deleted in the heart, resulting in a significant reduction in PKP2 protein expression. This tamoxifen-induced cardiomyocyte-specific deletion of the mouse PKP2 protein results in an ARVC model termed the PKP2-cKO mouse model.
[0179] Figure 7The design of the cardiac-specific PKP2 knockout mouse model for studying tamoxifen-induced treatment with AAV.STRV5-hTNNT2.PKP2a or AAV.STR V84-hTNNT2.PKP2a is shown. AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a was injected into mice of about 3 months of age via the tail vein at 5e13vg / kg. Five groups (two positive controls: Groups 2 and 3 in Table B; one negative control: Group 1 in Table B; and two treatment groups: Groups 4 and 5 in Table B) were used to evaluate the ability to express the human PKP2 gene in mouse heart tissue compared to wild-type and knockout mouse PKP2 levels. See Table B.
[0180] Table B:
[0181]
[0182] For cardiac-specific PKP2 deletion, mice were injected intraperitoneally with tamoxifen (0.1 mg / g body weight) for 4 consecutive days approximately 16 days after AAV injection. The mice were then observed for an additional 54 days to assess survival.
[0183] like Fig. 8A As shown in Table C, the positive control mice were "PKP2 wt / wt; Cre+" or "PKP2 fl / fl; Cre-", showing the highest survival probability, with most mice surviving for more than 52 days after induction (dpi). In contrast, the negative control mice with cardiac-specific PKP2 knockout ("PKP2 fl / fl; Cre+") only survived about 50 days. Notably, treatment of cardiac-specific PKP2 knockout mice with AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a resulted in the rescue of the PKP2 knockout phenotype and significantly prolonged the survival probability.
[0184] For the second cohort of Table B, cardiac-specific PKP2 knockout animals (see Table D below) were treated with AAV.STRV5-hTNNT2.PKP 2a as described above, and the study endpoint was day 54 or approximately 8 weeks after tamoxifen injection. The experimental design is shown in Table D.
[0185] In the second cohort, all unmasked animals in the positive control group (Pkp2 fl / fl; Cre- and Pkp2 wt / wt; Cre+) survived to the scheduled necropsy endpoint, while all mice in the untreated PKP2-cKO (Pkp2 fl / fl; Cre+) negative control group reached the testing institution's early euthanasia criteria prior to study endpoint, consistent with the disease model phenotype. Notably, all unmasked PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a survived to the scheduled necropsy endpoint, indicating treatment-mediated prolonged survival. (See Figure 8B , Table B and Table D)
[0186] Table C:
[0187]
[0188] Table D:
[0189]
[0190]
[0191] *Days after tamoxifen injection (dpi)
[0192] Example 6: Cardiac-specific expression of AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a PKP2 expression in a PKP2 knockout mouse model results in prolonged survival
[0193] The presence of the PKP2a transgene and the expression of PKP2 mRNA in a cardiac-specific PKP2 knockout mouse model following treatment with an AAV vector containing the PKP2 gene were evaluated. DNA and RNA extraction and analysis were performed as described in Example 4 above. Fig. 9A As shown, the results showed that the PKP2a transgene was detectable in the heart tissue of cardiac-specific PKP2 knockout mice treated with AAV.STRV5-hTNNT2.PKP2a vector or AAV.STRV84-hTNNT2.PKP2a vector. Fig. 9B As shown, the results showed that PKP2a mRNA was detectable in the heart tissue of mice treated with AAV.STRV 5-hTNNT2.PKP2a vector or AAV.STRV84-hTNNT2.PKP2a vector.
[0194] Treatment with AAV.STRV84-hTNNT2.PKP2a advantageously resulted in a log-fold greater copy number in the heart compared to treatment with the AAV.STRV5-hTNNT2.PKP2a vector. In addition, treatment with AAV.STRV84-hTNNT2.PKP2a advantageously resulted in a log-fold greater mRNA expression in the heart compared to treatment with the AAV.STRV5-hTNNT2.PKP2a vector. Copy number and mRNA expression in the liver were similar after treatment with both AAV vectors. Notably, Fig. 9B It was shown that expression of the TNNT2 promoter resulted in high expression of PKP2 in the heart, but very low expression in the liver. This differential expression has the beneficial effect of minimizing off-target effects during treatment with the AAV vectors disclosed herein.
[0195] The method described in Example 3 above was used to evaluate PKP2 protein expression after treatment of PKP2 cardiac knockout mice with AAV.STRV5-hTNNT2.PKP2a vector or AAV.STRV84-hTNNT2.PKP2a vector. Fig. 10A PKP2 protein was detected using the Jess automated western blotting system with anti-PKP2a-b (1:100) from ARP (Cat. No. 03-651101), and Fig. 10B Total protein in (loading control). Quantification shown in Table E was performed using Jess software and normalized to the mean of Group 2 (positive control).
[0196] like Fig. 10A and 10B As shown in Table E, treatment of cardiac-specific PKP2 knockout mice with AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a resulted in expression of PKP2 protein in cardiac tissue. In addition, treatment with AAV.STRV84-hTNNT2.PKP2a resulted in much higher PKP2 protein expression in the heart (1.71-fold relative to wild type) compared to treatment with AAV.STRV5-hTNNT2.PKP2a vector (0.52-fold relative to wild type), indicating that treatment with AAV particles comprising the disclosed AAV expression cassette of SEQ ID NO: 12 and a capsid protein having the amino acid sequence of SEQ ID NO: 15 is particularly effective in rescuing PKP2 levels and function in vivo.
[0197] Table E:
[0198]
[0199] Example 7: Heart after treatment with AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a Localization of PKP2 in desmosomes in a specific PKP2 knockout mouse model
[0200] Analysis of mouse heart tissue sections by immunohistochemistry showed results consistent with the molecular analysis ( Figures 11A-11E Specifically, PKP2 wt / wt;Cre+ and PKP2 fl / fl;Cre-, tamoxifen-treated (+control) mice showed widespread PKP2 signaling throughout the heart ( Fig.11A and 11B ), which were clearly aligned with the interlaminar region of cardiomyocyte cell-cell junctions, consistent with PKP2 localization to cardiac desmosomes, whereas cardiac-specific PKP2 knockout (PKP2 fl / fl, Cre+, tamoxifen-treated; control) animals exhibited minimal PKP2 signal in cardiac tissue sections ( Fig. 11C Notably, PKP2-cKO animals treated with AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a showed cardiac PKP2a signal throughout the heart and consistent localization with that observed in positive control animals after 10 weeks ( Fig.11D and 14E), thus providing further evidence for vector-derived PKP2a expression and confirming the localization of PKP2a within the appropriate cellular regions.
[0201] In summary, the results described herein demonstrate that treating mice lacking PKP2 function in cardiac tissue with an AAV vector disclosed herein comprising PKP2a (e.g., AAV.STRV47-hTNNT2.PKP2a, AAV.STRV5-hTNNT2.PKP2a, or AAV.ST RV84-hTNNT2.PKP2a) not only results in expression of PKP2 mRNA and protein in cardiac tissue, but also promotes precise localization of human PKP2 protein in desmosomes. These results also demonstrate that expression of human PKP2 from an AAV vector disclosed herein results in a significant increase in the survival of animals lacking PKP2 function in cardiac tissue. Finally, the expression of human PKP2 from an AAV vector disclosed herein is advantageously higher in the heart compared to the liver.
[0202] Example 8: Cardiac structural changes after treatment of cardiac-specific PKP2 knockout mice with AAV.STRV5-hTNNT2.PKP2a and significant improvement in heart function
[0203] Analysis of cardiac function and structure in PKP2-cKO mice by echocardiography revealed reduced left ventricular ejection fraction and increased left ventricular area compared with control mice with wild-type PKP2 function (WT; Cre+ mice and floxed; Cre- mice). Notably, PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a maintained an ejection fraction comparable to control animals and showed a delayed increase in right ventricular area ( Fig. 12A and 12B (Arrows point to AAV.STRV5-hTNNT2.PKP2a-treated mice). Even 42 days after tamoxifen induction, both cardiac parameters were significantly improved in AAV.STRV5-hTNNT2.PKP2a-treated mice compared with untreated PKP2-cKO mice, indicating treatment-mediated prevention of cardiac dysfunction and delayed progression of cardiac dilatation ( Fig. 12C and 12D Together, these data suggest that AAV.STRV5-mediated expression of PKP2 prevents the decline in cardiac function and delays the onset and progression of cardiac dilatation.
[0204] Analysis of mouse heart tissue by Western blotting revealed little or no expression of endogenous PKP2 in PKP2-cKO hearts, consistent with Cre-mediated deletion of Pkp2 exons 2 and 3. In contrast, PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a exhibited robust expression of human PKP2a in the heart, at levels approximately 1.5-fold higher than endogenous PKP2 levels ( Fig.13A and 13B ). Analysis of vector copy number (VCN) by qPCR showed that approximately 10 5 vector copies and about 0.5×10 per microgram of DNA in liver tissue 6 Further analysis of vector-derived PKP2a mRNA by RT-qPCR showed that 10 copies of PKP2a were expressed per 10 ng cDNA input in cardiac tissue. 4 -10 5 Despite higher VCN in the liver relative to the heart, PKP2a mRNA copies were approximately 500-fold lower in the liver, highlighting the cardiac-specific expression profile of the hTNNT2 promoter utilized in the cassette ( Fig. 13C and 13D ). Taken together, these data confirm expression of vector-derived PKP2a in mouse heart, while demonstrating minimal expression in liver.
[0205] Additional analysis of cardiac tissue by Masson's trichrome staining revealed extensive collagen deposition in the right ventricle of untreated PKP2-cKO mice ( Fig.14A), indicating the presence of pathological cardiac fibrosis. In contrast, mice with PKP2 function (+control; FL, Cre-) showed minimal collagen deposition in the right ventricle, indicating normal cardiac tissue. Notably, PKP2-cKO mice treated with AAV.STRV5-hTNNT2.PKP2a or AAV.STRV84-hTNNT2.PKP2a showed significantly less right ventricular (RV) fibrosis ( Fig. 14C and 14D ). Fig.15 Quantification of fibrosis in animals from both groups is shown ( Fig. 8A and 8B (See also Table B). Treatment with AAV.STRV84-hTNNT2.PKP2a reduced fibrosis levels to almost the level of the positive control.
[0206] In summary, the data described above clearly demonstrate that expression of PKP2 in an AAV-mediated method (e.g., using an AAV.STRV5 or AAV.STRV84 vector) can not only rescue PKP2 protein levels in a cardiac-specific PKP2 knockout mouse model, but can also restore the localization and function of PKP2 in these animals. The AAV-mediated PKP2 protein expression described herein inhibits the formation of fibrotic areas in cardiac tissue, thereby maintaining cardiac function. Therefore, the methods disclosed herein include expressing PKP2 using AAV vectors such as AAV.STRV5 and AAV.STRV84, which can alleviate pathologies associated with loss of PKP2 function, such as in arrhythmogenic cardiomyopathy.
[0207] Example 9: Dose finding and efficacy studies in the PKP2-cKO mouse model
[0208] This was an 85-day dose-finding study using 79 mice. The mice were injected with the AAV transgene IV in the tail vein on day 1. On day 16, the mice were induced intraperitoneally with tamoxifen. The mice were divided into 9 groups as shown in Table F. Group 1 was wild-type mice. Group 2 was PKP2 fl / fl Cre- mice. Group 3 was PKP2 fl / fl Cre+ mice. Group 4 was PKP2fl / fl Cre+ mice (mouse PKP2) given 3e12 vg / kg of AAV.STRV84-hTNNT2.mPKP2. Group 5 was PKP2 fl / fl Cre+ mice given 1e13 vg / kg of AAV.STRV84-hTNNT2.mPKP2. Group 6 was PKP2 fl / fl Cre+ mice given 3e13 vg / kg of AAV.STRV84-hTNNT2.mPKP2. Group 7 was PKP2 fl / fl Cre+ mice given 1e14 vg / kg of AAV.STRV84-mTNNT2.mPKP2. Group 8 was PKP2 fl / fl Cre+ mice given 1e13 vg / kg of AAV.STRV84-hTNNT2.PKP2. Group 9 was PKP2 fl / fl Cre+ mice given 1e14 vg / kg of AAV.STRV84-hTNNT2.PKP2. In summary, in this experiment, the ultra-low (UL) dose was 3e12, the low (L) dose was 1e13, the medium dose (M) was 3e13, and the high (H) dose was 1e14 vg / kg. For reference, the selected dose for the proof-of-concept (POC) study was 5e13 vg / kg.
[0209] Mice were evaluated using biweekly echocardiography. In addition, the biodistribution of AAV vectors and expression of the PKP2 transgene in mouse heart and liver tissues were analyzed as described below.
[0210] Table F:
[0211] Group genotype Total number of animals treat PKP2 Dosage (vg / kg) 1 PKP2 wt / wt;Cre+ 8 N / A - 0 2 PKP2 fl / fl;Cre- 10 N / A - 0 3 PKP2 fl / fl;Cre+ 10 N / A - 0 4 PKP2 fl / fl;Cre+ 10 STRV84 / mPKP2 Mouse 3e12 5 PKP2 fl / fl;Cre+ 10 STRV84 / mPKP2 Mouse 1e13 6 PKP2 fl / fl;Cre+ 10 STRV84 / mPKP2 Mouse 3e13 7 PKP2 fl / fl;Cre+ 10 STRV84 / mPKP2 Mouse 1e14 8 PKP2 fl / fl;Cre+ 5 STRV84 / hPKP2 people 1e13 9 PKP2 fl / fl;Cre+ 6 STRV84 / hPKP2 people 1e14
[0212] like Figures 16A-16B As shown, as the dose of human or mouse PKP2 was increased, the vector copy number of PKP2 DNA increased. This was true for both the heart and liver of the treated animals. Fig.16A involves data from groups 1-7, and Fig. 16B Relates to data from groups 1-3 and 8-9.
[0213] Figures 17A-17BA similar correlation between dose and PKP2 mRNA levels was shown. However, PKP2 mRNA levels in the heart of PKP2 treated animals continued to increase across the entire dose range, while levels in the liver were approximately 1e2 copies / 10 ng cDNA in all groups. Similarly, mPKP2 and hPKP2 had similar mRNA levels at similar doses.
[0214] Figure 18-21 is a Western blot showing changes in PKP2 levels based on treatment. Results for cardiac levels of mPKP2 ( Fig.18 ) are shown in Table G. The results of hPKP2 cardiac levels ( Fig.19 ) are shown in Table H. The results of mPKP2 liver levels ( Fig. 20 ) are shown in Table 1. The results of hPKP2 liver levels ( Fig.21 ) are shown in Table J.
[0215] Table G:
[0216]
[0217] Table H:
[0218]
[0219] Table I:
[0220]
[0221] Table J:
[0222]
[0223] In summary, vector copy number and mRNA expression in the heart increased with increasing doses of AAV-PKP2 administration. With increasing doses, vector copy number in the liver increased slightly, but mRNA levels were low and relatively similar in all dose groups. The results indicate that while levels of PKP2 protein in the heart increased with increasing doses, levels in the liver were not detected to be overexpressed at any dose. Without being bound by theory, it is believed that these results are contributed by the liver de-targeting distribution of the STRV84 capsid and the use of a cardiac-specific promoter. Western blot analysis of the heart showed that PKP2 expression was enhanced with increasing doses. Expression in both mouse and human transgenic treatment groups followed this pattern. Western blot analysis of the liver showed similar expression levels in all tested groups, including mPKP2 and hPKP2 treatment groups. Human and mouse transgenics showed comparable protein expression in the liver.
[0224] Figures 22A-22B showed that administration of transgenic mice ( Fig.22A ) or human transgenic ( Fig. 22B ) increased the survival probability of mice lacking PKP2 function in a dose-dependent manner.
[0225] Figures 23A-23F and 24A-24F show the dose of the human transgene at which the animals showed statistically improved health compared to untreated control mice. Echocardiographic data provide quantitative measures of cardiac structure and function. The graphs in these figures show the performance of unaffected healthy control hearts (two positive control groups (wt / wt, Cre+; NA and fl / fl, Cre-; NA)), as well as the effects of ARVC (untreated negative control group (fl / fl, Cre+; NA)), and therefore provide a measure of the extent to which AAV treatment preserves cardiac structure and function. Correlations between dose and phenotypic rescue were observed for the following parameters: Ejection fraction ( Fig.23A and Fig.24A ), left ventricular (LV) volume ( Fig. 23B and Fig. 24B ), stroke volume ( Fig.23C and Fig.24C ), shorten the score percentage ( Fig.23D and Fig.24D ), cardiac output ( Fig.23E and Fig.24E ) and left ventricular outflow tract velocity time integral (LVOT VTI) ( Fig.23F and Fig.24F ). It should be noted that all data are from the left side of the animal.
[0226] The foregoing is illustrative of the present invention and should not be construed as limiting the present invention.
[0227] Numbered implementation plan
[0228] The following list of embodiments is included for illustrative purposes only and is not intended to be comprehensive or limiting. The claimed subject matter is expressly not limited to the following embodiments.
[0229] Embodiment 1. A nucleic acid molecule comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, from 5' to 3':
[0230] a.5'AAV inverted terminal repeat (ITR);
[0231] b. Promoter;
[0232] c. Arrhythmogenic cardiomyopathy-associated transgenes; and
[0233] d. 3' AAV ITR.
[0234] Embodiment 2. The nucleic acid molecule of embodiment 1, wherein the promoter drives expression of the ACM-related transgene.
[0235] Embodiment 3. The nucleic acid molecule of embodiment 1 or 2, wherein the promoter is capable of expressing the transgene in cardiac cells.
[0236] Embodiment 4. A nucleic acid molecule as described in any of embodiments 1-3, wherein the promoter comprises a cardiac troponin T (TNNT2) promoter.
[0237] Embodiment 5. A nucleic acid molecule as described in Embodiment 4, wherein the TNNT2 promoter comprises a nucleic acid sequence derived from: (i) human TNNT2 promoter, (ii) chicken TNNT2 promoter, (iii) mouse TNNT2 promoter, or (iv) any combination thereof.
[0238] Embodiment 6. The nucleic acid molecule of embodiment 5, wherein the TNNT2 promoter comprises a human TNNT2 promoter.
[0239] Embodiment 7. The nucleic acid molecule of any one of embodiments 4-6, wherein the TNNT2 promoter comprises the nucleic acid sequence of SEQ ID NO: 4 or a sequence having at least 90% identity thereto.
[0240] Embodiment 8. The nucleic acid molecule of any one of embodiments 1-7, wherein the transgene encodes Desmophorin-2.
[0241] Embodiment 9. The nucleic acid molecule of any one of embodiments 1-8, wherein the transgene encodes human desmoplakin-2.
[0242] Embodiment 10. The nucleic acid molecule of any one of embodiments 1-9, wherein the transgene encodes isoform 2a of human desmoplakin-2.
[0243] Embodiment 11. The nucleic acid molecule of embodiment 10, wherein isoform 2a of human desmoplakin-2 comprises the amino acid sequence of SEQ ID NO: 1 or a sequence having at least 90% identity thereto.
[0244] Embodiment 12. The nucleic acid molecule of any one of embodiments 1-11, wherein the transgene encodes RNA transcript variant 2a of the PKP2 gene.
[0245] Embodiment 13. The nucleic acid molecule of any one of embodiments 1-12, wherein the transgene comprises a PKP2 gene.
[0246] Embodiment 14. The nucleic acid molecule of embodiment 13, wherein the PKP2 gene is a human PKP2 gene.
[0247] Embodiment 15. The nucleic acid molecule of any one of embodiments 1-14, wherein the transgene comprises the nucleic acid sequence of SEQ ID NO: 2 or a sequence at least 90% identical thereto.
[0248] Embodiment 16. The nucleic acid molecule of any one of embodiments 1-15, wherein at least one of the 5' ITR and the 3' ITR is about 110 to about 160 nucleotides in length.
[0249] Embodiment 17. The nucleic acid molecule of any one of embodiments 1-16, wherein the 5' ITR is the same length as the 3' ITR.
[0250] Embodiment 18. The nucleic acid molecule of any one of Embodiments 1-17, wherein the 5' ITR and the 3' ITR have different lengths.
[0251] Embodiment 19. The nucleic acid molecule of any one of embodiments 1-18, wherein the 5' ITR and the 3' ITR are each about 141 nucleotides in length.
[0252] Embodiment 20. A nucleic acid molecule as described in any of embodiments 1-19, wherein at least one of the 5'ITR and the 3'ITR is isolated or derived from the genome of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV.
[0253] Embodiment 21. The nucleic acid molecule of any one of embodiments 1-20, wherein the 5' ITR and the 3' ITR are each isolated or derived from the genome of AAV2.
[0254] Embodiment 22. The nucleic acid molecule of any one of embodiments 1-21, wherein the 5'ITR comprises the sequence of SEQ ID NO:5.
[0255] Embodiment 23. The nucleic acid molecule of any one of embodiments 1-22, wherein the 3'ITR comprises the sequence of SEQ ID NO:6.
[0256] Embodiment 24. The nucleic acid molecule of any one of embodiments 1-23, wherein the AAV expression cassette comprises an intron.
[0257] Embodiment 25. The nucleic acid molecule of embodiment 24, wherein the intron is derived from a human β-globin gene.
[0258] Embodiment 26. The nucleic acid molecule of embodiment 24 or embodiment 25, wherein the intron comprises the nucleic acid sequence of SEQ ID NO: 7 or a sequence having at least 90% identity thereto.
[0259] Embodiment 27. The nucleic acid molecule of any one of embodiments 1-26, wherein the AAV expression cassette comprises a polyadenylation signal.
[0260] Embodiment 28. The nucleic acid molecule of embodiment 27, wherein the polyadenylation signal is isolated or derived from the polyadenylation signal of one or more of the following genes: Simian virus 40 (SV40), rBG, α-globin, β-globin, human collagen, human growth hormone (hGH), polyoma virus, human growth hormone (hGH), or bovine growth hormone (bGH).
[0261] Embodiment 29. The nucleic acid molecule of embodiment 27 or embodiment 28, wherein the AAV expression cassette comprises a bGH polyadenylation signal.
[0262] Embodiment 30. The nucleic acid molecule of embodiment 29, wherein the bGH polyadenylation signal comprises the nucleic acid sequence of SEQ ID NO: 8 or a sequence at least 90% identical thereto.
[0263] Embodiment 31. The nucleic acid molecule of any one of embodiments 1-30, wherein the AAV expression cassette comprises at least one stuffer sequence.
[0264] Embodiment 32. The nucleic acid molecule of embodiment 31, wherein the at least one stuffer sequence comprises the nucleic acid sequence of SEQ ID NO: 9 or a sequence having at least 90% identity thereto.
[0265] Embodiment 33. A nucleic acid molecule as described in embodiment 31, wherein the at least one stuffer sequence comprises the nucleic acid sequence of SEQ ID NO: 9 or a portion thereof.
[0266] Embodiment 34. The nucleic acid molecule of any one of embodiments 1-33, wherein the AAV expression cassette comprises a Kozak sequence.
[0267] Embodiment 35. A nucleic acid molecule as described in embodiment 34, wherein the Kozak sequence comprises the nucleic acid sequence of SEQ ID NO: 10 or a sequence with at least 90% identity thereto; or the nucleic acid sequence of acagccacc or a sequence with at least 90% identity thereto.
[0268] Embodiment 36. The nucleic acid molecule of any one of embodiments 1-35, wherein the AAV expression cassette comprises an enhancer.
[0269] Embodiment 37. The nucleic acid molecule of any one of embodiments 1-36, wherein the AAV expression cassette comprises the nucleic acid sequence of SEQ ID NO: 12 or a sequence at least 90% identical thereto.
[0270] Embodiment 38. A plasmid comprising the nucleic acid molecule of any one of embodiments 1-37.
[0271] Embodiment 39. A cell comprising the nucleic acid molecule of any one of embodiments 1-37 or the plasmid of embodiment 38.
[0272] Embodiment 40. A method for producing a recombinant AAV vector, the method comprising contacting an AAV producer cell with a nucleic acid molecule as described in any one of embodiments 1-37 or a plasmid as described in embodiment 38.
[0273] Embodiment 41. A recombinant AAV vector produced by the method described in Embodiment 40.
[0274] Embodiment 42. A recombinant AAV vector as described in embodiment 41, wherein the vector belongs to a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV and bovine AAV.
[0275] Embodiment 43. The recombinant AAV vector of embodiment 41 or embodiment 42, wherein the recombinant AAV vector is a single-stranded AAV (ssAAV).
[0276] Embodiment 44. The recombinant AAV vector of embodiment 41 or embodiment 42, wherein the recombinant AAV vector is a self-complementary AAV (scAAV).
[0277] Embodiment 45. A recombinant AAV vector as described in any of Embodiments 41-44, wherein the AAV vector comprises a capsid protein of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV.
[0278] Embodiment 46. A recombinant AAV vector as described in any of Embodiments 41-45, wherein the AAV vector comprises a capsid protein having one or more substitutions or mutations compared to a wild-type AAV capsid protein.
[0279] Embodiment 47. The recombinant AAV vector of any one of embodiments 41-46, wherein the AAV vector comprises a capsid protein comprising:
[0280] a. (i) the amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto, or
[0281] b. (ii) the amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto, or
[0282] c. (iii) the amino acid sequence of SEQ ID NO: 15, or a sequence at least 90% identical thereto.
[0283] Embodiment 48. A recombinant AAV vector as described in Embodiment 47, wherein the AAV vector comprises a capsid protein, and the capsid protein comprises the amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto.
[0284] Embodiment 49. The recombinant AAV vector of Embodiment 48, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 13.
[0285] Embodiment 50. A recombinant AAV vector as described in Embodiment 47, wherein the AAV vector comprises a capsid protein, and the capsid protein comprises the amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto.
[0286] Embodiment 51. A recombinant AAV vector as described in Embodiment 50, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 14.
[0287] Embodiment 52. A recombinant AAV vector as described in Embodiment 47, wherein the AAV vector comprises a capsid protein, and the capsid protein comprises the amino acid sequence of SEQ ID NO: 15 or a sequence having at least 90% identity thereto.
[0288] Embodiment 53. A recombinant AAV vector as described in Embodiment 52, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15.
[0289] Embodiment 54. A composition comprising: (a) a nucleic acid molecule as described in any of embodiments 1-37, a plasmid as described in embodiment 38, a cell as described in embodiment 39, or a recombinant AAV vector as described in any of embodiments 41-53; and (b) a pharmaceutically acceptable carrier.
[0290] Embodiment 55. A method for expressing an arrhythmogenic cardiomyopathy-associated transgene in a tissue, comprising: contacting the tissue with a nucleic acid molecule as described in any of embodiments 1-37, a plasmid as described in embodiment 38, a recombinant AAV vector as described in any of embodiments 41-53, or a composition as described in embodiment 54, thereby expressing the arrhythmogenic cardiomyopathy-associated transgene in the tissue.
[0291] Embodiment 56. The method of embodiment 55, wherein the tissue comprises one or more cells and one or more desmosomal junctions.
[0292] Embodiment 57. The method of embodiment 55 or embodiment 56, wherein the one or more cells are cardiac cells, endothelial cells, skin cells, bladder cells, or gastrointestinal mucosal cells.
[0293] Embodiment 58. A method as described in Embodiment 57, wherein the one or more cells are cardiac cells.
[0294] Embodiment 59. The method of any one of embodiments 55-58, wherein the contacting step is performed in vitro, ex vivo, or in vivo.
[0295] Embodiment 60. The method of embodiment 59, wherein the contacting step is performed in a subject in need thereof.
[0296] Embodiment 61. The method of embodiment 60, wherein the contacting step comprises administering to the subject a therapeutically effective amount of a nucleic acid molecule, plasmid, recombinant AAV vector, or composition.
[0297] Embodiment 62. The method of embodiment 60 or embodiment 61, wherein the subject has or is at risk of developing arrhythmogenic cardiomyopathy.
[0298] Embodiment 63. A method for treating arrhythmogenic cardiomyopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a nucleic acid molecule as described in any of embodiments 1-37, a plasmid as described in embodiment 38, a cell as described in embodiment 39, a recombinant AAV vector as described in any of embodiments 41-53, or a composition as described in embodiment 54, thereby treating the subject's arrhythmogenic cardiomyopathy.
[0299] Embodiment 64. The method of embodiment 63, wherein the subject has or is at risk of developing arrhythmogenic cardiomyopathy.
[0300] Embodiment 65. A method as described in any of Embodiments 62-64, wherein the arrhythmogenic cardiomyopathy is arrhythmogenic right ventricular cardiomyopathy.
[0301] Embodiment 66. A method as described in any of embodiments 62-65, wherein the arrhythmogenic cardiomyopathy is associated with, promoted by, or caused by a genetic mutation.
[0302] Embodiment 67. A method as described in Embodiment 66, wherein the genetic mutation includes a mutation in the PKP2 gene.
[0303] Embodiment 68. The method of embodiment 67, wherein the mutation in the PKP2 gene results in PKP2 haploinsufficiency.
[0304] Embodiment 69. A method as described in any of Embodiments 62-68, wherein the method comprises reducing the severity of arrhythmogenic cardiomyopathy: delaying the onset or progression of arrhythmogenic cardiomyopathy; and / or eliminating symptoms of arrhythmogenic cardiomyopathy.
[0305] Embodiment 70. The method of embodiment 69, wherein the symptoms of arrhythmogenic cardiomyopathy include: (a) reentrant ventricular tachycardia, (b) syncope, (c) sudden death, or (d) any combination thereof.
[0306] Embodiment 71. A method as described in any of embodiments 62-70, wherein the arrhythmogenic cardiomyopathy is associated with: (a) reduced mechanical stability between cardiomyocytes of the subject, (b) disrupted gap junctions in the subject's cardiac tissue, (c) reduced sodium currents in the subject's cardiac tissue, (d) right ventricular myocardial fibrosis, or (e) any combination thereof.
[0307] Embodiment 72. A method as described in any of Embodiments 62-71, wherein the method comprises increasing the mechanical stability between cardiomyocytes of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0308] Embodiment 73. A method as described in any of Embodiments 62-72, wherein the method comprises improving the function of gap junctions in cardiac tissue of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0309] Embodiment 74. A method as described in any of Embodiments 62-73, wherein the method comprises increasing sodium current in cardiac tissue of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0310] Embodiment 75. A method as described in any of Embodiments 62-74, wherein the method comprises reducing right ventricular myocardial fibrosis in the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0311] Embodiment 76. A method as described in any of Embodiments 62-75, wherein the method comprises increasing the left ventricular ejection fraction of the heart compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0312] Embodiment 77. A method as described in any of Embodiments 62-76, wherein the method comprises reducing the right ventricular area of the heart compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0313] Embodiment 78. A method as described in any of Embodiments 62-77, wherein the method comprises extending the survival of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
[0314] Embodiment 79. The method of any one of Embodiments 60-78, wherein the subject is a human subject.
[0315] Embodiment 80. The method of any one of Embodiments 60-79, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector or the composition is administered to cardiac tissue of the subject.
[0316] Embodiment 81. The method of embodiment 80, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector or the composition is administered to the left atrium, the right atrium, the left ventricle, the right ventricle and / or the septum.
[0317] Embodiment 82. The method of any one of embodiments 60-81, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector, or the composition is administered to the subject by intravenous administration, intra-arterial administration, intra-aortic administration, direct cardiac injection, coronary artery perfusion, or any combination thereof.
Claims
1. A nucleic acid molecule comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, from 5' to 3': (i) 5' AAV inverted terminal repeat (ITR); (ii) promoter; (iii) Arrhythmogenic cardiomyopathy-associated transgenes; and (iv) 3' AAV ITR.
2. The nucleic acid molecule of claim 1, wherein the promoter drives expression of the ACM-related transgene.
3. The nucleic acid molecule of claim 1 or 2, wherein the promoter is capable of expressing the transgene in cardiac cells.
4. The nucleic acid molecule of any one of claims 1-3, wherein the promoter comprises the cardiac troponin T (TNNT2) promoter.
5. The nucleic acid molecule of claim 4, wherein the TNNT2 promoter comprises a nucleic acid sequence derived from: (i) human TNNT2 promoter, (ii) chicken TNNT2 promoter, (iii) mouse TNNT2 promoter, or (iv) any combination thereof.
6. The nucleic acid molecule of claim 5, wherein the TNNT2 promoter comprises a human TNNT2 promoter.
7. The nucleic acid molecule of any one of claims 4 to 6, wherein the TNNT2 promoter comprises the nucleic acid sequence SEQ ID NO: 4 or a sequence having at least 90% identity thereto.
8. The nucleic acid molecule of any one of claims 1-7, wherein the transgene encodes Desmophorin-2.
9. The nucleic acid molecule of any one of claims 1-8, wherein the transgene encodes human desmosomal plaque protein-2.
10. The nucleic acid molecule of any one of claims 1-9, wherein the transgene encodes isoform 2a of human desmoplastin-2.
11. The nucleic acid molecule of claim 10, wherein isoform 2a of human desmoplakin-2 comprises the amino acid sequence of SEQ ID NO: 1 or a sequence having at least 90% identity thereto.
12. The nucleic acid molecule of any one of claims 1-11, wherein the transgene encodes RNA transcript variant 2a of the PKP2 gene.
13. The nucleic acid molecule of any one of claims 1-12, wherein the transgene comprises a PKP2 gene.
14. The nucleic acid molecule of claim 13, wherein the PKP2 gene is a human PKP2 gene.
15. The nucleic acid molecule of any one of claims 1 to 14, wherein the transgene comprises the nucleic acid sequence of SEQ ID NO: 2 or a sequence having at least 90% identity thereto.
16. The nucleic acid molecule of any one of claims 1-15, wherein at least one of the 5' ITR and the 3' ITR is about 110 to about 160 nucleotides in length.
17. The nucleic acid molecule of any one of claims 1 to 16, wherein the 5' ITR is the same length as the 3' ITR.
18. The nucleic acid molecule of any one of claims 1-17, wherein the 5' ITR and the 3' ITR have different lengths.
19. The nucleic acid molecule of any one of claims 1-18, wherein the 5' ITR and the 3' ITR are each about 141 nucleotides in length.
20. The nucleic acid molecule of any one of claims 1-19, wherein at least one of the 5'ITR and the 3'ITR is isolated or derived from the genome of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV.
21. The nucleic acid molecule of any one of claims 1-20, wherein the 5' ITR and the 3' ITR are each isolated or derived from the genome of AAV2.
22. The nucleic acid molecule of any one of claims 1-21, wherein the 5' ITR comprises the sequence of SEQ ID NO:
5.
23. The nucleic acid molecule of any one of claims 1-22, wherein the 3'ITR comprises the sequence of SEQ ID NO:
6.
24. The nucleic acid molecule of any one of claims 1-23, wherein the AAV expression cassette comprises an intron.
25. The nucleic acid molecule of claim 24, wherein the intron is derived from the human β-globin gene.
26. The nucleic acid molecule of claim 24 or claim 25, wherein the intron comprises the nucleic acid sequence of SEQ ID NO: 7 or a sequence having at least 90% identity thereto.
27. The nucleic acid molecule of any one of claims 1-26, wherein the AAV expression cassette comprises a polyadenylation signal.
28. The nucleic acid molecule of claim 27, wherein the polyadenylation signal is a polyadenylation signal isolated or derived from one or more of the following genes: Simian virus 40 (SV40), rBG, α-globin, β-globin, human collagen, human growth hormone (hGH), polyoma virus, human growth hormone (hGH), or bovine growth hormone (bGH).
29. The nucleic acid molecule of claim 27 or claim 28, wherein the AAV expression cassette comprises a bGH polyadenylation signal.
30. The nucleic acid molecule of claim 29, wherein the bGH polyadenylation signal comprises the nucleic acid sequence of SEQ ID NO: 8 or a sequence at least 90% identical thereto.
31. The nucleic acid molecule of any one of claims 1-30, wherein the AAV expression cassette comprises at least one stuffer sequence.
32. The nucleic acid molecule of claim 31, wherein the at least one stuffer sequence comprises the nucleic acid sequence of SEQ ID NO: 9 or a sequence having at least 90% identity thereto.
33. The nucleic acid molecule of claim 31, wherein the at least one stuffer sequence comprises the nucleic acid sequence of SEQ ID NO: 9 or a portion thereof.
34. The nucleic acid molecule of any one of claims 1-33, wherein the AAV expression cassette comprises a Kozak sequence.
35. The nucleic acid molecule of claim 34, wherein the Kozak sequence comprises the nucleic acid sequence of SEQ ID NO: 10 or a sequence having at least 90% identity thereto; or the nucleic acid sequence of acagccacc or a sequence having at least 90% identity thereto.
36. The nucleic acid molecule of any one of claims 1-35, wherein the AAV expression cassette comprises an enhancer.
37. The nucleic acid molecule of any one of claims 1-36, wherein the AAV expression cassette comprises the nucleic acid sequence SEQ ID NO: 12 or a sequence having at least 90% identity thereto.
38. A plasmid comprising the nucleic acid molecule of any one of claims 1-37.
39. A cell comprising the nucleic acid molecule of any one of claims 1-37 or the plasmid of claim 38.
40. A method for producing a recombinant AAV vector, the method comprising contacting an AAV producer cell with a nucleic acid molecule as described in any one of claims 1-37 or a plasmid as described in claim 38.
41. A recombinant AAV vector produced by the method of claim 40.
42. A recombinant AAV vector as described in claim 41, wherein the vector is of a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV and bovine AAV.
43. The recombinant AAV vector of claim 41 or claim 42, wherein the recombinant AAV vector is a single-stranded AAV (ssAAV).
44. The recombinant AAV vector of claim 41 or claim 42, wherein the recombinant AAV vector is a self-complementary AAV (scAAV).
45. The recombinant AAV vector of any one of claims 41-44, wherein the AAV vector comprises a capsid protein of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, avian AAV or bovine AAV.
46. The recombinant AAV vector of any one of claims 41-45, wherein the AAV vector comprises a capsid protein having one or more substitutions or mutations compared to a wild-type AAV capsid protein.
47. The recombinant AAV vector of any one of claims 41-46, wherein the AAV vector comprises a capsid protein comprising: a. (i) the amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto, or b. (ii) the amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto, or c. (iii) the amino acid sequence of SEQ ID NO: 15, or a sequence at least 90% identical thereto.
48. A recombinant AAV vector as described in claim 47, wherein the AAV vector comprises a capsid protein, and the capsid protein comprises the amino acid sequence of SEQ ID NO: 13 or a sequence having at least 90% identity thereto.
49. A recombinant AAV vector as described in claim 48, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO:
13.
50. The recombinant AAV vector of claim 47, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 14 or a sequence having at least 90% identity thereto.
51. A recombinant AAV vector as described in claim 50, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO:
14.
52. The recombinant AAV vector of claim 47, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15 or a sequence having at least 90% identity thereto.
53. A recombinant AAV vector as described in claim 52, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO:
15.
54. A composition comprising: (a) a nucleic acid molecule as described in any one of claims 1-37, a plasmid as described in claim 38, a cell as described in claim 39, or a recombinant AAV vector as described in any one of claims 41-53; and (b) a pharmaceutically acceptable carrier.
55. A method for expressing arrhythmogenic cardiomyopathy-related transgene in a tissue, wherein include: The tissue is contacted with a nucleic acid molecule as described in any one of claims 1-37, a plasmid as described in claim 38, a recombinant AAV vector as described in any one of claims 41-53, or a composition as described in claim 54, thereby expressing the arrhythmogenic cardiomyopathy-associated transgene in the tissue.
56. The method of claim 55, wherein the tissue comprises one or more cells, and one or more desmosomal junctions.
57. The method of claim 55 or claim 56, wherein the one or more cells are cardiac cells, endothelial cells, skin cells, bladder cells, or gastrointestinal mucosal cells.
58. The method of claim 57, wherein the one or more cells are cardiac cells.
59. The method of any one of claims 55-58, wherein the contacting step is performed in vitro, ex vivo, or in vivo.
60. The method of claim 59, wherein the contacting step is performed in vivo in a subject in need thereof.
61. The method of claim 60, wherein the contacting step comprises administering to the subject a therapeutically effective amount of a nucleic acid molecule, plasmid, recombinant AAV vector, or composition.
62. The method of claim 60 or claim 61, wherein the subject has or is at risk of developing arrhythmogenic cardiomyopathy.
63. A method for treating arrhythmogenic cardiomyopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a nucleic acid molecule as described in any one of claims 1-37, a plasmid as described in claim 38, a cell as described in claim 39, a recombinant AAV vector as described in any one of claims 41-53, or a composition as described in claim 54, thereby treating the subject's arrhythmogenic cardiomyopathy.
64. The method of claim 63, wherein the subject has or is at risk of developing arrhythmogenic cardiomyopathy.
65. The method of any one of claims 62-64, wherein the arrhythmogenic cardiomyopathy is arrhythmogenic right ventricular cardiomyopathy.
66. The method of any one of claims 62-65, wherein the arrhythmogenic cardiomyopathy is associated with, promoted by, or caused by a genetic mutation.
67. The method of claim 66, wherein the genetic mutation comprises a mutation in the PKP2 gene.
68. The method of claim 67, wherein the mutation in the PKP2 gene results in PKP2 haploinsufficiency.
69. The method of any one of claims 62-68, wherein the method comprises reducing the severity of ACM: delaying the onset or progression of ACM; and / or eliminating symptoms of ACM.
70. The method of claim 69, wherein the symptoms of ACM include: (a) reentrant ventricular tachycardia, (b) syncope, (c) sudden death, or (d) any combination thereof.
71. The method of any one of claims 62-70, wherein the arrhythmogenic cardiomyopathy is associated with (a) reduced mechanical stability between cardiomyocytes of the subject, (b) disrupted gap junctions in cardiac tissue of the subject, (c) reduced sodium currents in cardiac tissue of the subject, (d) right ventricular myocardial fibrosis, or (e) any combination thereof.
72. The method of any one of claims 62-71, wherein the method comprises increasing mechanical stability between cardiomyocytes of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject has not been administered the therapeutically effective amount.
73. The method of any one of claims 62-72, wherein the method comprises improving the function of gap junctions in cardiac tissue of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject has not been administered the therapeutically effective amount.
74. The method of any one of claims 62-73, wherein the method comprises increasing sodium current in cardiac tissue of the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject prior to administration of the therapeutically effective amount, wherein the control subject has not been administered the therapeutically effective amount.
75. The method of any one of claims 62-74, wherein the method comprises reducing right ventricular myocardial fibrosis in the subject compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject before administration of the therapeutically effective amount, wherein the control subject has not been administered the therapeutically effective amount.
76. The method of any one of claims 62-75, wherein the method comprises increasing the left ventricular ejection fraction of a heart compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject prior to administration of the therapeutically effective amount, wherein the control subject has not been administered the therapeutically effective amount.
77. The method of any one of claims 62-76, wherein the method comprises reducing right ventricular area of the heart compared to a control subject having arrhythmogenic cardiomyopathy, or compared to the subject prior to administration of the therapeutically effective amount, wherein the control subject has not been administered the therapeutically effective amount.
78. The method of any one of claims 62-77, wherein the method comprises extending the survival of the subject as compared to a control subject having arrhythmogenic cardiomyopathy, or as compared to the expected survival of the subject prior to administration of the therapeutically effective amount, wherein the control subject is not administered the therapeutically effective amount.
79. The method of any one of claims 60-78, wherein the subject is a human subject.
80. The method of any one of claims 60-79, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector or the composition is administered to cardiac tissue of the subject.
81. The method of claim 80, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector or the composition is administered to the left atrium, the right atrium, the left ventricle, the right ventricle and / or the septum.
82. The method of any one of claims 60-81, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector or the composition is administered to the subject by intravenous administration, intra-arterial administration, intra-aortic administration, direct cardiac injection, coronary artery perfusion, or any combination thereof.
Citation Information
Patent Citations
Compositions and methods for treatment of muscular dystrophy
US10286085B2
Method and apparatus for device controlled gene expression for cardiac protection
US8538520B2
Intracoronary device and method of use thereof
US8708948B2
Optical depolarization of cardiac tissue
US9138596B2
